A Prospective Multicenter Randomized Controlled Trial on the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients

The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. This measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. Hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in MHD patients. Due to the intermittent nature of hemodialysis treatment, MHD patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of MHD patients. Serum potassium variability can better reflect the potassium homeostasis in MHD patients. In addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of MHD patients. At present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. In this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.

开始日期2025-03-01

申办/合作机构

山东第一医科大学第一附属医院（山东省千佛山医院、山东省牙病防治指导中心）

NCT06578078

/ Recruiting临床3期IIT

A Randomized Clinical Trial to Define the Best Strategy for the Management of Heart Failure and Chronic Kidney Disease Among Elderly Patients With or at High Risk of hyperKalemia in Span by Optimizing the Use of RAASi With SZC

Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.

开始日期2024-10-03

申办/合作机构-

IRCT20130313012810N11

/ SuspendedN/AIIT

Comparative bioequivalence study of sodium zirconium cyclosilicate (SZC-9) in the forms of 5 and 10 g sachets vs brand medicine (Lokelma made by AztraZeneca)

开始日期2024-08-31

申办/合作机构

Tabriz University of Medical Sciences

100 项与环硅酸锆钠相关的临床结果

登录后查看更多信息

100 项与环硅酸锆钠相关的转化医学

登录后查看更多信息

100 项与环硅酸锆钠相关的专利（医药）

登录后查看更多信息

268

项与环硅酸锆钠相关的文献（医药）

2026-01-13·CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION

Potential therapeutic effects of zinc and copper chlorophyllins in viral respiratory infections: recent developments and future directions

Review

作者: Vasilev, Krasimir ; Clark, Nicole ; Bright, Richard ; Mangoni, Arduino A. ; Heimann, Kirsten

Zinc and copper are essential trace elements that regulate immunity and inflammation, with antiviral effects that may help combat respiratory viruses like SARS-CoV-2, the virus responsible for COVID-19. These effects include reducing cytokine storms and acute respiratory distress syndrome (ARDS). However, zinc and copper uptake is limited by homeostasis mechanisms, reducing their effectiveness. Sodium copper chlorophyllin (SCC) and sodium zinc chlorophyllin (SZC), nontoxic chlorophyll derivatives, may overcome these limitations by delivering higher intracellular levels of these metals. Evidence suggests SCC and SZC exhibit antiviral activity against SARS-CoV-2 and other respiratory viruses by inhibiting viral entry, replication, and release from infected cells. Animal studies show that SCC can lower viral loads and reduce ARDS-like symptoms. Additionally, SCC and SZC may suppress proinflammatory cytokines, potentially preventing or reducing the severity of cytokine storms. This review highlights the antiviral and anti-inflammatory effects of zinc and copper, explores the therapeutic potential of SCC and SZC in viral respiratory infections, and discusses future research directions to optimize these treatments.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice

Article

作者: Merlo, Andrea ; Mongelli, Valentina ; Degli Esposti, Luca ; Maurizi, Anna Rita ; Leogrande, Melania ; Cosentino, Nicola ; Nugnes, Marta ; Gnesi, Marco ; Daniel, Francesca

AIMS:

Hyperkalemia (HK) is prevalent in patients with chronic kidney disease (CKD) and heart failure, particularly those on renin-angiotensin-aldosterone system inhibitors (RAASi). However, HK treatment often necessitates RAASi discontinuation. Sodium zirconium cyclosilicate (SZC), reimbursed in Italy since 2021, offers a new treatment option for HK. This study aimed to assess real-world SZC use and resulting economic rebounds in Italy.

METHODS:

Using administrative databases of healthcare entities covering about 6 million residents, patients with at least one prescription of SZC from Jan-2022 to Jun-2023 were identified. Patients receiving other potassium binders after SZC initiation were excluded. A logistic regression model estimated odds ratios (OR) with 95% confidence interval (95%CI) for predictors of long-term SZC use (>90 days), including age, sex, CKD status, and comorbidities. Univariate regression identified the potential association between each individual predictor and the likelihood of long-term treatment, followed by multivariate analysis adjusted for confounders. A backward stepwise logistic regression method retained only significant predictors, enhancing model accuracy.

RESULTS:

The study identified 355 SZC-treated patients (mean age 70.4 years, 64.2% male). CKD was found in 69.3% (47.6% on dialysis), with common comorbidities including hypertension (57.5%), diabetes (43.4%), and heart failure (23.4%). RAASi use was observed in 68.7% before SZC initiation, and RAASi discontinuation was lower in long-term SZC users compared to short-term SZC users (41.2 vs. 56.6%, p = 0.048). Short-term SZC treatment (≤90 days) was more frequent (83.1%) and predicted by dialysis (OR = 0.22). Healthcare costs over 6 months averaged €7,943 for short-term users (dialysis: €3,452) and €6,647 for long-term users (dialysis: €1,130).

CONCLUSIONS:

This real-world study showed that nearly 17% of patients continued SZC therapy for ≥90 days. Long-term therapy was associated with lower RAASi discontinuation and reduced healthcare costs due to hospitalizations and outpatient specialist services, suggesting that SZC can potentially provide clinical and economic benefits for HK management.

2025-12-02·JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy

Article

作者: Pyles, Dixie ; Shigle, Amanda Jo ; Kovacic Scherrer, Nicole ; Zarfoss Ponce, Erika

Abstract:

Background:

Sulfamethoxazole/trimethoprim is utilized to treat various infections, but its use can be limited by hyperkalaemia. Sodium zirconium cyclosilicate is a potassium binder, which has been shown to lower potassium in chronic kidney disease.

Objectives:

To determine the safety and efficacy of sodium zirconium cyclosilicate for patients experiencing sulfamethoxazole/trimethoprim-induced hyperkalaemia.

Methods:

Patients receiving treatment with sulfamethoxazole/trimethoprim and sodium zirconium cyclosilicate therapy concomitantly for at least 48 h between 2021 and 2024 were identified. Efficacy was evaluated by potassium change from baseline, proportion of patients achieving normokalaemia by 24 and 48 h, and time to potassium normalization. Safety was assessed by evaluating hypokalaemia occurrence while on sodium zirconium cyclosilicate therapy.

Results:

There were 22 patients included. The median total daily dose of sulfamethoxazole/trimethoprim was 960 mg or 15 mg/kg/day. Fifteen patients (68%) were treated for confirmed Stenotrophomonas maltophilia or Pneumocystis pneumonia infections. Eight patients (36%) received a loading dose of sodium zirconium cyclosilicate 10 g three times daily for 48 h prior to receiving 10 g daily. The median difference in potassium at baseline and the end of sodium zirconium cyclosilicate therapy was 0.9 mmol/L. Fourteen patients of 22 (64%) and 19 of 21 patients (90%) achieved normokalaemia by 24 and 48 h, respectively. The median time to potassium normalization was 23.5 h. There were no instances of hypokalaemia while on sodium zirconium cyclosilicate therapy.

Conclusions:

Sodium zirconium cyclosilicate was efficacious at lowering elevated potassium in patients receiving sulfamethoxazole/trimethoprim therapy without inducing hypokalaemia. This suggests sodium zirconium cyclosilicate may be considered in patients with treatment-limiting hyperkalaemia due to sulfamethoxazole/trimethoprim, especially when sulfamethoxazole/trimethoprim is preferred therapy.

项与环硅酸锆钠相关的新闻（医药）

2025-12-23

·三弟药闻

20251222-23 中国国家药品监督管理局药品审评中心(CDE)受理信息--化药

1 氟哌啶醇口服溶液受理号：CYHS2504360（国产化药仿制上市申请）药品名称：氟哌啶醇口服溶液企业名称：海南斯达制药有限公司；海南斯达制药有限公司靶点与机制：丁酰苯类抗精神病药，通过拮抗中枢多巴胺D2受体，具有较强的抗精神病作用和镇吐作用，口服溶液剂型适合精神分裂症、躁狂症等患者。注册分类：3类（仿制药）2 贝美前列素涂剂受理号：CYHL2500228（国产化药临床申请）药品名称：贝美前列素涂剂企业名称：南京正科医药股份有限公司靶点与机制：前列腺素类似物，通过增加葡萄膜巩膜途径房水外流降低眼内压，涂剂剂型可能用于睫毛增长或特定眼部疾病的外用治疗。注册分类：3类（仿制药）3-4 RX608片受理号：CXHL2501445、CXHL2501444（国产新药临床申请）药品名称：RX608片企业名称：苏州润新生物科技有限公司靶点与机制：RX608是一款针对BRAF V600E突变的选择性小分子抑制剂注册分类：1类（创新药）5-7 VG081821AC片受理号：CXHL2501443、CXHL2501442、CXHL2501441（国产新药临床申请）药品名称：VG081821AC片企业名称：浙江春禾医药科技有限公司靶点与机制：A2aR拮抗剂(腺苷A2a受体拮抗剂) 注册分类：1类（创新药）8 美芬那敏铵糖浆受理号：JTH2500199（进口化药申请）药品名称：美芬那敏铵糖浆企业名称：乐信药业有限公司；乐信药业有限公司；广州市乐尔健贸易发展有限公司靶点与机制：复方感冒药，具体成分与机制未公开，糖浆剂型可能用于缓解感冒症状。注册分类：未标注（进口申请）9 盐酸帕洛诺司琼受理号：JTH2500198（进口化药申请）药品名称：盐酸帕洛诺司琼企业名称：HAS HEALTHCARE ADVANCED SYNTHESIS SA (HAS) ；HAS HEALTHCARE ADVANCED SYNTHESIS SA (HAS) ；上海凯茂生物医药有限公司靶点与机制：第二代5-HT3受体拮抗剂，通过高选择性、高亲和力阻断5-HT3受体，强效预防化疗引起的急性和迟发性恶心呕吐，本次为原料药或中间体进口申请。注册分类：未标注（进口申请）10 磷奈匹坦盐酸盐受理号：JTH2500197（进口化药申请）药品名称：磷奈匹坦盐酸盐企业名称：HAS HEALTHCARE ADVANCED SYNTHESIS SA (HAS) ；HAS HEALTHCARE ADVANCED SYNTHESIS SA (HAS) ；上海凯茂生物医药有限公司靶点与机制：神经激肽-1（NK-1）受体拮抗剂，通过阻断P物质与NK-1受体结合，用于预防化疗引起的急性和迟发性恶心呕吐，常与5-HT3受体拮抗剂联用。本次为原料药或中间体进口申请。注册分类：未标注（进口申请）11 乳酸钠林格注射液受理号：CYHS2504359（国产化药仿制上市申请）药品名称：乳酸钠林格注射液企业名称：浙江都邦药业股份有限公司；浙江都邦药业股份有限公司靶点与机制：复方电解质溶液，提供钠、钾、钙、氯和乳酸根离子，乳酸根在肝脏代谢为碳酸氢根，用于补充体液、电解质并纠正酸中毒。注册分类：4类（仿制药）12 多种微量元素注射液(Ⅲ) 受理号：CYHS2504358（国产化药仿制上市申请）药品名称：多种微量元素注射液(Ⅲ) 企业名称：石家庄四药有限公司；石家庄四药有限公司靶点与机制：微量元素补充剂，提供锌、铜、锰、铬等多种微量元素，用于肠外营养支持，预防和治疗微量元素缺乏症。注册分类：4类（仿制药）13 对乙酰氨基酚布洛芬口服混悬液受理号：CYHS2504357（国产化药仿制上市申请）药品名称：对乙酰氨基酚布洛芬口服混悬液企业名称：华益药业科技(安徽)有限公司；华益药业科技(安徽)有限公司靶点与机制：复方解热镇痛药，对乙酰氨基酚抑制中枢前列腺素合成，布洛芬抑制外周前列腺素合成，协同作用，口服混悬液剂型适合儿童。注册分类：3类（仿制药）14 瑞舒伐他汀钙片受理号：CYHS2504356（国产化药仿制上市申请）药品名称：瑞舒伐他汀钙片企业名称：浙江诺得药业有限公司；浙江诺得药业有限公司靶点与机制：HMG-CoA还原酶抑制剂，通过抑制胆固醇合成的限速酶，强效降低低密度脂蛋白胆固醇，用于高胆固醇血症和混合型血脂异常。注册分类：4类（仿制药）15 佩玛贝特片受理号：CYHS2504355（国产化药仿制上市申请）药品名称：佩玛贝特片企业名称：浙江花园药业有限公司；浙江花园药业有限公司靶点与机制：PPARα激动剂，通过激活过氧化物酶体增殖物激活受体α，降低甘油三酯水平，用于高甘油三酯血症。注册分类：4类（仿制药）16-18 磷酸奥司他韦胶囊受理号：CYHS2504354、CYHS2504353、CYHS2504352（国产化药仿制上市申请）药品名称：磷酸奥司他韦胶囊企业名称：西洲医药科技(浙江)有限公司；浙江北生药业汉生制药有限公司靶点与机制：神经氨酸酶抑制剂，通过抑制流感病毒神经氨酸酶，阻止病毒从宿主细胞释放，用于甲型和乙型流感的治疗和预防。注册分类：4类（仿制药）19-20 洛索洛芬钠贴剂受理号：CYHS2504351、CYHS2504350（国产化药仿制上市申请）药品名称：洛索洛芬钠贴剂企业名称：内蒙古白医制药股份有限公司；内蒙古白医制药股份有限公司靶点与机制：非甾体抗炎药，通过抑制环氧合酶减少前列腺素合成，贴剂剂型用于局部镇痛抗炎，如肌肉痛、关节痛。注册分类：4类（仿制药）21 注射用多黏菌素E甲磺酸钠受理号：CYHL2500227（国产化药临床申请）药品名称：注射用多黏菌素E甲磺酸钠企业名称：河北圣雪大成制药有限责任公司靶点与机制：多黏菌素类抗生素，通过破坏革兰阴性菌外膜和细胞膜导致细菌死亡，是治疗多重耐药革兰阴性菌（如铜绿假单胞菌、鲍曼不动杆菌）感染的最后防线药物之一。注册分类：3类（仿制药）22 氟[18F]妥西吡注射液受理号：CYHL2500226（国产化药临床申请）药品名称：氟[18F]妥西吡注射液企业名称：杭州亦立医药有限公司靶点与机制：正电子发射断层扫描（PET）显像剂，氟-18标记的淀粉样蛋白显像剂，用于阿尔茨海默病等神经退行性疾病的淀粉样斑块显像诊断。注册分类：3类（仿制药）23 注射用甲磺酸加贝酯受理号：CYHB2550408（国产化药补充申请）药品名称：注射用甲磺酸加贝酯企业名称：山西阳和医药技术有限公司；山西普恒制药有限公司靶点与机制：蛋白酶抑制剂，通过抑制胰蛋白酶、激肽释放酶等，用于急性轻型（水肿型）胰腺炎的治疗。注册分类：原6类（补充申请）24-26 单硝酸异山梨酯缓释胶囊(Ⅲ) 受理号：CYHB2502567、CYHB2502566、CYHB2502565（国产化药补充申请）药品名称：单硝酸异山梨酯缓释胶囊(Ⅲ) 企业名称：武汉爱民制药股份有限公司；武汉爱民制药股份有限公司靶点与机制：硝酸酯类药物，在体内代谢释放一氧化氮，激活鸟苷酸环化酶，松弛血管平滑肌，缓释剂型用于冠心病、慢性心力衰竭的长期治疗。注册分类：未标注（补充申请）27-28 注射用头孢呋辛钠受理号：CYHB2502564、CYHB2502563（国产化药补充申请）药品名称：注射用头孢呋辛钠企业名称：湖南恒生制药股份有限公司；湖南恒生制药股份有限公司靶点与机制：第二代头孢菌素，通过抑制细菌细胞壁合成，对革兰阳性菌和部分革兰阴性菌有良好抗菌活性，用于敏感菌引起的感染。注册分类：未标注（补充申请）29-30 氯化锶[89Sr]注射液受理号：CYHB2502562、CYHB2502561（国产化药补充申请）药品名称：氯化锶[89Sr]注射液企业名称：四川中核高通药业有限公司；成都中核高通同位素股份有限公司靶点与机制：放射性治疗药物，锶-89发射的β射线可在骨转移灶选择性浓聚，产生局部放射治疗作用，用于前列腺癌、乳腺癌等恶性肿瘤骨转移引起的骨痛。注册分类：原6类（补充申请）31-32 氯化锶[89Sr]注射液受理号：CYHB2502560、CYHB2502559（国产化药补充申请）药品名称：氯化锶[89Sr]注射液企业名称：四川中核高通药业有限公司；成都中核高通同位素股份有限公司靶点与机制：放射性核素治疗药物，锶-89发射的β射线可在骨转移灶选择性浓集，产生局部内照射，用于缓解前列腺癌、乳腺癌等恶性肿瘤骨转移引起的骨痛。本次为补充申请。注册分类：原6类（补充申请）33-35, 37 D3S-002片受理号：CXHL2501440、CXHL2501439、CXHL2501438、CXHL2501436（国产新药临床申请）药品名称：D3S-002片企业名称：德昇济医药（无锡）有限公司靶点与机制：ERK1 x ERK2抑制剂注册分类：1类（创新药）36 瑞加诺生注射液受理号：CXHL2501437（国产新药临床申请）药品名称：瑞加诺生注射液企业名称：江西银涛药业股份有限公司靶点与机制：选择性A2A腺苷受体激动剂，江西银涛药业开发的2.4类改良型新药，通过激活冠状动脉A2A受体，产生短效、强效的血管舒张作用，用于心脏负荷试验的药物激发，辅助诊断冠心病。注册分类：2.4类（改良型新药）38 D3S-001胶囊受理号：CXHL2501435（国产新药临床申请）药品名称：D3S-001胶囊企业名称：德昇济医药（无锡）有限公司靶点与机制：KRAS-G12C 注册分类：1类（创新药）39 BL0020注射液受理号：CXHL2501434（国产新药临床申请）药品名称：BL0020注射液企业名称：上海弼领生物技术有限公司靶点与机制：BL0020是一款用于精准递送TOPO 1抑制剂的新型肿瘤微环境靶向的纳米偶联药物。该药物具有长循环时间、肿瘤组织高富集特性，能在肿瘤微环境特异性酶作用下实现连接子断裂并释放有效载荷。注册分类：1类（创新药）40-41 INT-210胶囊受理号：CXHL2501433、CXHL2501432（国产新药临床申请）药品名称：INT-210胶囊企业名称：宜坤行健生物医药（上海）有限公司靶点与机制：具体靶点与机制未知，适应症为炎症性肠炎注册分类：1类（创新药）42-43 KC1036片受理号：CXHL2501431、CXHL2501430（国产新药临床申请）药品名称：KC1036片企业名称：北京康辰药业股份有限公司靶点与机制：KC1036通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。KC1036具有较强的VEGFR血管靶向，抑制肿瘤细胞生长；通过抑制AXL，可以改善宿主的抗肿瘤免疫应答，从而避免肿瘤的免疫逃逸。截至目前，KC1036 Ⅲ期临床研究首例受试者顺利入组。注册分类：1类（创新药）44 H021肠溶片受理号：CXHL2501429（国产新药临床申请）药品名称：H021肠溶片企业名称：江苏柯菲平医药股份有限公司靶点与机制：H021肠溶片是一种由江苏柯菲平医药股份有限公司研发的口服小分子创新药，主要用于治疗中重度活动性溃疡性结肠炎注册分类：1类（创新药）45-46 环硅酸锆钠散受理号：JYHB2500697、JYHB2500696（进口化药补充申请）药品名称：环硅酸锆钠散企业名称：AstraZeneca AB；AndersonBrecon, Inc. 靶点与机制：口服钾离子结合剂，在消化道内选择性地捕获钾离子，降低血清钾浓度，用于治疗高钾血症。本次为补充申请。注册分类：5.1类（补充申请）47 伏立康唑片受理号：JYHB2500695（进口化药补充申请）药品名称：伏立康唑片企业名称：Aspen Pharma Schweiz GmbH；Sandoz Private Limited 靶点与机制：三唑类广谱抗真菌药，通过抑制真菌细胞色素P450依赖的14α-甾醇去甲基化酶，干扰麦角固醇合成，用于侵袭性曲霉病、念珠菌病等。本次为补充申请。注册分类：5.2类（补充申请）48 盐酸维拉帕米注射液受理号：CYHS2504349（国产化药仿制上市申请）药品名称：盐酸维拉帕米注射液企业名称：江苏福邦药业有限公司；江苏福邦药业有限公司靶点与机制：非二氢吡啶类钙通道阻滞剂，通过抑制心肌和血管平滑肌钙离子内流，降低心肌收缩力、减慢房室传导、扩张血管，用于快速型室上性心律失常、心绞痛、高血压。注册分类：3类（仿制药）49-50 利伐沙班口崩片受理号：CYHS2504348、CYHS2504347（国产化药仿制上市申请）药品名称：利伐沙班口崩片企业名称：江西施美药业股份有限公司；江西施美药业股份有限公司靶点与机制：直接Xa因子抑制剂，通过选择性抑制凝血因子Xa，阻断凝血级联反应，口崩片剂型提高用药便利性，用于预防和治疗静脉血栓栓塞症。注册分类：3类（仿制药）51 酮咯酸氨丁三醇片受理号：CYHS2504346（国产化药仿制上市申请）药品名称：酮咯酸氨丁三醇片企业名称：华东医药（西安）博华制药有限公司；华东医药（西安）博华制药有限公司靶点与机制：非甾体抗炎药，通过抑制环氧合酶（COX-1和COX-2），减少前列腺素合成，用于中重度急性疼痛的短期治疗。注册分类：3类（仿制药）52-53 奥氮平片受理号：CYHS2504345、CYHS2504344（国产化药仿制上市申请）药品名称：奥氮平片企业名称：湖南千金湘江药业股份有限公司；湖南千金湘江药业股份有限公司靶点与机制：非典型抗精神病药，通过拮抗多巴胺D2受体和5-羟色胺5-HT2A受体，用于精神分裂症、双相情感障碍躁狂发作的治疗。注册分类：4类（仿制药）54 中性腹膜透析液（碳酸氢盐-G1.5%）受理号：CYHS2504343（国产化药仿制上市申请）药品名称：中性腹膜透析液（碳酸氢盐-G1.5%）企业名称：石家庄四药有限公司；石家庄四药有限公司靶点与机制：腹膜透析液，采用碳酸氢盐缓冲体系，更符合生理状态，1.5%葡萄糖浓度产生低渗透压，用于终末期肾病的持续性不卧床腹膜透析。注册分类：3类（仿制药）55 培哚普利氨氯地平片（III）受理号：CYHS2504342（国产化药仿制上市申请）药品名称：培哚普利氨氯地平片（III）企业名称：淄博万杰制药有限公司；淄博万杰制药有限公司靶点与机制：复方降压药，培哚普利为血管紧张素转换酶抑制剂，氨氯地平为钙通道阻滞剂，通过不同机制协同降压，用于高血压治疗。注册分类：4类（仿制药）56 唑尼沙胺片受理号：CYHS2504341（国产化药仿制上市申请）药品名称：唑尼沙胺片企业名称：湖南尚众合生物医药有限公司；天地恒一制药股份有限公司靶点与机制：磺胺类抗癫痫药，通过多机制（阻滞钠通道、T型钙通道，弱抑制碳酸酐酶）减少神经元异常放电，用于癫痫部分性发作的辅助治疗。注册分类：3类（仿制药）57 氯化钾注射液受理号：CYHB2502558（国产化药补充申请）药品名称：氯化钾注射液企业名称：华润双鹤利民药业（济南）有限公司；华润双鹤利民药业（济南）有限公司靶点与机制：电解质补充剂，钾离子参与维持细胞渗透压、酸碱平衡、神经冲动传导和肌肉收缩，用于治疗和预防低钾血症。注册分类：未标注（补充申请）58 盐酸氨基葡萄糖胶囊受理号：CYHB2502557（国产化药补充申请）药品名称：盐酸氨基葡萄糖胶囊企业名称：北京葡立药业有限公司；北京葡立药业有限公司靶点与机制：骨关节炎慢作用药，为软骨基质合成提供前体，刺激软骨细胞产生蛋白多糖，抑制损伤软骨的酶，用于骨关节炎的辅助治疗。注册分类：4类（补充申请）59-60 骨化三醇软胶囊受理号：CYHB2502556、CYHB2502555（国产化药补充申请）药品名称：骨化三醇软胶囊企业名称：郑州泰丰制药有限公司；河南泰丰生物科技有限公司靶点与机制：活性维生素D3，通过与维生素D受体结合，调节钙磷代谢，促进肠道钙吸收和骨矿化，软胶囊剂型用于慢性肾功能衰竭、甲状旁腺功能减退等引起的维生素D缺乏。注册分类：4类（补充申请） 61-63 利巴韦林含片受理号：CYHB2502554、CYHB2502553、CYHB2502552（国产化药补充申请）药品名称：利巴韦林含片企业名称：吉林省德商药业股份有限公司；吉林海通制药有限公司靶点与机制：核苷类广谱抗病毒药，通过抑制肌苷单磷酸脱氢酶，干扰病毒RNA的合成，从而抑制多种DNA和RNA病毒的复制。含片剂型可使药物在口腔局部缓慢释放，用于呼吸道合胞病毒引起的病毒性肺炎、支气管炎，或局部用于疱疹性口腔炎。注册分类：原6类（补充申请）64-65 红霉素肠溶片受理号：CYHB2502551、CYHB2502550（国产化药补充申请）药品名称：红霉素肠溶片企业名称：吉林省德商药业股份有限公司；吉林海通制药有限公司靶点与机制：大环内酯类抗生素，通过与细菌核糖体50S亚基结合，抑制细菌蛋白质合成，起到抑菌或杀菌作用。肠溶片剂型可保护药物免受胃酸破坏，确保在肠道碱性环境中崩解吸收，用于敏感菌引起的呼吸道、皮肤软组织等感染。注册分类：原6类（补充申请）66 复方环磷酰胺片受理号：CYHB2502549（国产化药补充申请）药品名称：复方环磷酰胺片企业名称：吉林省德商药业股份有限公司；吉林海通制药有限公司靶点与机制：烷化剂类细胞毒药物，在体内代谢为活性产物，与DNA发生交叉联结，破坏DNA结构，抑制肿瘤细胞增殖。复方制剂通常含有其他成分以减轻副作用或协同作用，用于恶性淋巴瘤、多发性骨髓瘤、乳腺癌、卵巢癌等多种恶性肿瘤的化疗。注册分类：原6类（补充申请）67-68 INT-210胶囊受理号：CXHL2501428、CXHL2501427（国产新药临床申请）药品名称：INT-210胶囊企业名称：宜坤行健生物医药（上海）有限公司靶点与机制：INT - 210胶囊为化学药物，适应症为炎症性肠病。炎症性肠病是累及胃肠道的慢性非特异性炎症注册分类：1类（创新药）69 H021肠溶片受理号：CXHL2501426（国产新药临床申请）药品名称：H021肠溶片企业名称：江苏柯菲平医药股份有限公司靶点与机制：H021肠溶片是一种由江苏柯菲平医药股份有限公司研发的口服小分子创新药，主要用于治疗中重度活动性溃疡性结肠炎70 BTP4327 受理号：CXHL2501425（国产新药临床申请）药品名称：BTP4327 企业名称：江苏诺和必拓新药研发有限公司；北京阳光诺和药物研究股份有限公司；北京百奥药业有限责任公司靶点与机制：具体靶点未公开注册分类：2.3类（改良型新药）71-73 HSK46575片受理号：CXHL2501424、CXHL2501423、CXHL2501422（国产新药临床申请）药品名称：HSK46575片企业名称：辽宁海思科制药有限公司靶点与机制：CYP11A1抑制剂(细胞色素P450家族成员11A1抑制剂) 注册分类：1类（创新药）74-76 胰酶肠溶胶囊受理号：JYHZ2500297、JYHZ2500296、JYHZ2500295（进口化药再注册）药品名称：胰酶肠溶胶囊企业名称：Abbott Laboratories GmbH; Shanghai Abbott Pharmaceutical Co., Ltd. 靶点与机制：消化酶替代疗法，含胰蛋白酶、胰淀粉酶、胰脂肪酶等多种活性酶，在肠道内释放，帮助消化食物中的脂肪、蛋白质和碳水化合物，用于胰腺外分泌功能不全（如慢性胰腺炎、囊性纤维化、胰腺切除术后）。肠溶胶囊可保护酶免受胃酸破坏。注册分类：未标注（进口再注册）77 吲哚美辛搽剂受理号：JYHZ2500294（进口化药再注册）药品名称：吲哚美辛搽剂企业名称：Kowa Company, Ltd.; Kowa Pharmaceuticals (China) Co., Ltd. 靶点与机制：非甾体抗炎药，通过抑制环氧合酶（COX），减少前列腺素等炎症介质的合成，搽剂剂型用于局部镇痛抗炎，缓解肌肉痛、关节痛、软组织损伤等引起的疼痛和炎症。注册分类：未标注（进口再注册）78 AZD5305 受理号：JXHL2500389（进口化药临床申请）药品名称：AZD5305 企业名称：AstraZeneca AB; AstraZeneca Investment (China) Co., Ltd. 靶点与机制：AZD5305是一种高选择性的PARP1抑制剂，旨在克服第一代PARP抑制剂的血液学毒性，用于治疗携带同源重组修复缺陷的肿瘤。注册分类：1类（创新药）79 阿达帕林凝胶受理号：CYHS2504340（国产化药仿制上市申请）药品名称：阿达帕林凝胶企业名称：湖北长江瑞益医药科技有限公司；湖北舒邦药业有限公司靶点与机制：第三代维A酸类药物，通过选择性结合维A酸受体，调节毛囊皮脂腺导管角质形成细胞的分化，溶解微粉刺并具有抗炎作用，凝胶剂型用于寻常痤疮的治疗。注册分类：4类（仿制药）80-81 巴瑞替尼片受理号：CYHS2504339（国产化药仿制上市申请）药品名称：巴瑞替尼片企业名称：海南海灵化学制药有限公司靶点与机制：JAK1/JAK2抑制剂，通过抑制Janus激酶（JAK）信号通路，减少多种炎症细胞因子（如IL-6、IFN-γ）的产生，用于类风湿关节炎、特应性皮炎等自身免疫性疾病的治疗。注册分类：4类（仿制药）82-84 草酸艾司西酞普兰口服溶液受理号：CYHS2504337、CYHS2504336、CYHS2504335（国产化药仿制上市申请）药品名称：草酸艾司西酞普兰口服溶液企业名称：哈尔滨市康隆药业有限责任公司靶点与机制：选择性5-羟色胺再摄取抑制剂，通过高选择性抑制突触前膜对5-羟色胺的再摄取，增加突触间隙5-羟色胺浓度，从而发挥抗抑郁和抗焦虑作用。口服溶液剂型适合儿童、老年人或吞咽困难患者。注册分类：3类（仿制药）85 硫酸氨基葡萄糖胶囊受理号：CYHS2504334（国产化药仿制上市申请）药品名称：硫酸氨基葡萄糖胶囊企业名称：江西铜鼓仁和制药有限公司靶点与机制：软骨保护剂，为合成蛋白多糖和胶原蛋白提供前体，抑制损伤软骨的酶（如胶原酶），并刺激软骨细胞代谢，用于骨关节炎的辅助治疗。注册分类：4类（仿制药）86-87 苯磺酸左氨氯地平片受理号：CYHS2504333、CYHS2504332（国产化药仿制上市申请）药品名称：苯磺酸左氨氯地平片企业名称：湖南千金湘江药业股份有限公司靶点与机制：钙通道阻滞剂，左旋氨氯地平为活性成分，通过阻滞血管平滑肌细胞钙离子内流，舒张外周动脉血管，降低血压，用于高血压和心绞痛的治疗。注册分类：4类（仿制药）88 环吡酮胺乳膏受理号：CYHB2502548（国产化药补充申请）药品名称：环吡酮胺乳膏企业名称：江苏知原药业股份有限公司靶点与机制：广谱抗真菌药，通过高选择性螯合真菌细胞内的多价金属离子，抑制其金属酶活性，干扰细胞呼吸和物质转运，从而抑制真菌生长。乳膏剂型用于皮肤浅部真菌感染，如手足癣、体股癣、花斑癣等。注册分类：原6类（补充申请）89 利福平胶囊受理号：CYHB2502547（国产化药补充申请）药品名称：利福平胶囊企业名称：吉林省德商药业股份有限公司；吉林海通制药有限公司靶点与机制：利福霉素类抗生素，通过与细菌DNA依赖的RNA聚合酶β亚单位结合，抑制RNA合成起始，对结核分枝杆菌具有强大杀菌作用，是抗结核治疗的一线药物。注册分类：未标注（补充申请）90-92 RGT-274-CR胶囊受理号：CXHL2501419（国产新药临床申请）药品名称：RGT-274-CR胶囊企业名称：上海齐鲁锐格医药研发有限公司靶点与机制：GLP-1R激动剂(胰高血糖素样肽-1激动剂) 注册分类：1类（创新药）注册分类：1类（创新药）93-95 AZD9750 受理号：CXHL2501416、CXHL2501415、CXHL2501414（国产新药临床申请）药品名称：AZD9750 企业名称：阿斯利康全球研发（中国）有限公司靶点与机制：AR 降解剂注册分类：1类（创新药）

2025-12-07

·阿斯利康中国

2025版国家基本医疗保险药品目录正式公布，11款阿斯利康创新药（含新增、续约和转乙类）将惠及广大中国患者

12月7日，2025创新药高质量发展大会在广州召开，会议发布2025年《国家基本医疗保险、生育保险和工伤保险药品目录》，包括谈判新增、谈判续约和转乙类的11款阿斯利康产品将惠及广大中国患者。调整后的新版医保药品目录将于2026年1月1日起正式实施。 3款创新药首次纳入医保目录荃科得®（卡匹色替片）康可期®（马来酸阿可替尼片）凡舒卓®（本瑞利珠单抗注射液） 3款创新药共新增3项适应症纳入医保目录沃瑞沙®（赛沃替尼片）新增用于治疗携带间质-上皮转化因子 (MET) 外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者的适应症。泰瑞沙®（甲磺酸奥希替尼片）新增用于接受含铂放化疗期间或之后未出现疾病进展及具有表皮生长因子 (EGFR) 外显子19缺失或外显子21 (L858R) 置换突变的局部晚期、不可切除（III期）非小细胞肺癌 (NSCLC) 成人患者的治疗的适应症。利普卓®（奥拉帕利片）新增用于接受过新辅助或辅助化疗的携带有害或疑似有害胚系BRCA突变 (gBRCAm)、人表皮生长因子受体2 (HER2) 阴性早期高风险乳腺癌成人患者的辅助治疗的适应症。 4款创新药成功续约康可期®（阿可替尼胶囊）利倍卓®（环硅酸锆钠散）舒立瑞®（依库珠单抗注射液）科赛优®（硫酸氢司美替尼胶囊） 1款创新药转入常规目录乙类安达释®（达格列净二甲双胍缓释片（I））一直以来，阿斯利康持续推动科学与创新，聚焦中国患者亟需的治疗领域，已带来40多款创新药，并积极携手多方，不断提升药品可及性和可负担性。未来，阿斯利康将始终秉持“以患者为中心”的理念，聚焦未满足的临床需求，持续为中国患者带来改变生命的药物，并携手多元合作伙伴，助力优质医疗资源惠及更广泛的人群，促进共同健康，为“健康中国2030”战略目标早日实现和中国医疗健康事业高质量发展贡献力量。林骁阿斯利康中国总经理阿斯利康中国生物制药业务总经理很高兴看到阿斯利康多款创新药纳入2025版国家医保目录，这是提升药品可及性、减轻患者负担的重要一步。在慢病防治方面，中国患病人群数量庞大，存在巨大未被满足的治疗需求。中国约有400万重度哮喘患者，其中近80%为重度嗜酸粒细胞性哮喘1。此次本瑞利珠单抗纳入医保，能助力更多患者长期规范治疗。未来，我们将加速引入创新疗法，并持续携手多方力量，提升创新药可及性和可负担性，为中国公共卫生事业的高质量发展注入持续动力。关冬梅阿斯利康中国肿瘤业务总经理此次阿斯利康多款肿瘤创新药和新适应症纳入医保目录，意味着更多肿瘤患者有机会受益于精准、个体化的创新治疗方案。阿斯利康始终与健康中国2030癌症防治目标同心同行。秉持“让癌症不再成为致死主因”的愿景，我们将围绕肺癌、乳腺癌、血液肿瘤、消化道肿瘤等中国高发癌种，加速引入创新药物，帮助更多患者延长生存、改善生活质量，并通过多方合作提高药物可及性，为实现“到2030年癌症五年生存率提升至46.6%”的宏伟目标贡献力量。胡轶清阿斯利康中国副总裁罕见病事业部负责人罕见病长期面临治疗选择有限、支付压力大的挑战。此次医保目录调整，是政策端对罕见病用药需求的积极回应，为罕见病家庭提供可持续、可负担的治疗保障。未来，阿斯利康将持续聚焦罕见病患者的未满足需求，加速引进全球创新疗法，同时深化与医保、商保及社会慈善机构的协作，构建多层次保障体系，切实提升可及性。我们也将继续推动罕见病诊疗规范化，为患者点亮生命的希望，让每一个罕见病患者都有机会成为社会栋梁。首次纳入医保目录荃科得®（卡匹色替片）卡匹色替于今年4月在华获批联合氟维司群用于转移性阶段至少接受过一种内分泌治疗后疾病进展，或在辅助治疗期间或完成辅助治疗后12个月内复发的激素受体 (HR) 阳性、人表皮生长因子受体2 (HER2) 阴性且伴有一种或多种PIK3CA/AKT1/PTEN改变的局部晚期或转移性乳腺癌成人患者。卡匹色替是一款First in class的AKT抑制剂，能阻断PIK3CA/AKT1/PTEN改变导致的通路过度激活，填补了HR+HER2-晚期乳腺癌伴PIK3CA或AKT1或PTEN改变的临床靶向治疗空白，为HR阳性晚期乳腺癌患者提供了更多创新治疗选择。康可期®（马来酸阿可替尼片）马来酸阿可替尼片为本次纳入医保目录的新药，用于慢性淋巴细胞白血病 (CLL)/小淋巴细胞淋巴瘤 (SLL) 患者、以及经治套细胞淋巴瘤 (MCL) 患者的适应症。 CLL/SLL、MCL等血液肿瘤的临床诊疗长期面临着传统药物安全性不足、复发率高、老年患者治疗棘手等痛点。阿可替尼是全球首个获批的第二代高选择性BTK抑制剂，马来酸阿可替尼片是基于阿可替尼胶囊的迭代升级，片剂与胶囊具有生物等效性，助力提升长期用药依从性，进而帮助CLL/SLL、R/R MCL患者实现高质量生存。凡舒卓®（本瑞利珠单抗注射液）本瑞利珠单抗是精准靶向嗜酸性粒细胞 (EOS) 的抗IL-5R生物制剂，用于儿童（6至＜12岁）、12岁及以上青少年和成人重度嗜酸粒细胞性哮喘 (SEA) 的维持治疗。纳入本次医保目录的适应症为12岁及以上青少年和成人重度嗜酸粒细胞性哮喘 (SEA) 的维持治疗。中国有近400万重度哮喘患者，约80%为SEA。这是一种以气道 (EOS) 炎症为主的哮喘亚型，通常表现为EOS增高。此类患者常面临急性发作更频繁、肺功能恶化、甚至有死亡风险。本瑞利珠单抗拥有独特的双重机制，能迅速降低血液与组织中的EOS水平，不仅为SEA患者提供更精准高效的治疗选择，纳入医保后也为患者的长期规范治疗奠定了重要基础。新增适应症纳入医保目录沃瑞沙®（赛沃替尼片）新增用于治疗携带间质-上皮转化因子 (MET) 外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者的适应症。赛沃替尼*是中国首个获批的选择性MET抑制剂，助力为MET基因突变的肺癌患者带来更高的治疗可及性和更优的生存质量。 *由阿斯利康与和黄医药共同开发，并由阿斯利康商业化。泰瑞沙®（甲磺酸奥希替尼片）新增用于接受含铂放化疗期间或之后未出现疾病进展及具有表皮生长因子 (EGFR) 外显子19缺失或外显子21 (L858R) 置换突变的局部晚期、不可切除（III期）非小细胞肺癌 (NSCLC) 成人患者的治疗的适应症。 Ⅲ期肺癌分为可切除、潜在切除和不可切除三大类，其中不可切除的Ⅲ期非小细胞肺癌患者占大多数，病程进展最为严峻，一直是临床治疗的难点。奥希替尼治疗EGFR突变Ⅲ期不可切除肺癌的适应症填补了几十年来的临床空白，对该类肺癌患者来说是一个重大突破，为他们带来长生存的希望。利普卓®（奥拉帕利片）新增用于接受过新辅助或辅助化疗的携带有害或疑似有害胚系BRCA突变 (gBRCAm)、人表皮生长因子受体2 (HER2) 阴性早期高风险乳腺癌成人患者的辅助治疗的适应症。携带BRCA突变的乳腺癌患者的5年无病生存率仅为73.3%2，在疾病复发和生存期方面的预后更差。奥拉帕利*是中国首个且唯一**获批用于胚系BRCA突变早期高风险乳腺癌的PARP抑制剂，此次纳入医保将进一步提升gBRCA突变、HER2阴性的早期高风险乳腺癌患者对创新治疗的可及和可支付性。 *与默沙东合作开发。 **截至2025年12月4日，最新查询CDE官网中药物获批“胚系BRCA突变早期高风险乳腺癌”信息的结果。成功续约康可期®（阿可替尼胶囊）成功续约经治慢性淋巴细胞白血病 (CLL)/小淋巴细胞淋巴瘤 (SLL) 患者、以及经治套细胞淋巴瘤 (MCL) 患者的适应症。 MCL、CLL等血液肿瘤的发病群体以老年群体为主，常伴有基础疾病，难以耐受传统化疗，一线治疗后复发率较高。作为全球首个获批的第二代高选择性BTK抑制剂，阿可替尼为患者提供以疾病控制和延长生存为目标的创新治疗选择。利倍卓®（环硅酸锆钠散）环硅酸锆钠散是首个在中国上市的创新型降钾药物，用于治疗成人高钾血症，填补了国内高钾血症治疗领域近60年的空白期。高钾血症是慢性肾脏病 (CKD) 和心力衰竭 (HF) 的常见并发症,可能导致严重的心律失常，甚至心脏骤停，危及患者生命。环硅酸锆钠采用创新离子捕获技术，对钾离子具有高选择性，且不被人体吸收或代谢，通过粪便排出体外，为我国高钾血症患者带来降钾控钾新选择。舒立瑞®（依库珠单抗注射液）依库珠单抗注射液是全球首个获批、中国医保目录内唯一可同时用于PNH、aHUS和成人难治性gMG治疗的C5补体抑制剂，填补临床药物治疗空白。目前中国唯一*获批适用于全年龄段人群的阵发性睡眠性血红蛋白尿症 (PNH) 治疗的C5补体抑制剂，目前中国唯一*获批治疗非典型溶血性尿毒症综合征 (aHUS) 的生物制剂，目前中国唯一*获批治疗抗乙酰胆碱受体 (AChR) 抗体阳性的难治性全身型重症肌无力成人患者的生物制剂。 *截至2025年12月5日。科赛优®（硫酸氢司美替尼胶囊） NF1-PN通常在患儿出生时或出生后不久即可出现，儿童期及青春期生长最快，瘤体可广泛生长，并浸润周围组织，造成严重的容貌畸形及功能障碍，致残、致畸率高。硫酸氢司美替尼胶囊是全球首个获批用于儿童NF1-PN的MEK抑制剂，填补临床药物治疗空白。司美替尼是选择性MEK1/2抑制剂，通过阻断RAF- MEK-ERK信号通路，抑制肿瘤细胞的增殖和存活，改善患儿及其家庭生活质量，助力患儿和家长回归学校与工作岗位。转入常规目录乙类安达释®（达格列净二甲双胍缓释片（I））达格列净二甲双胍缓释片（I）是首个达格列净（SGLT2i）和二甲双胍缓释剂（双胍类药物）的复方制剂。每日服用一次，配合饮食控制和运动，适用于适合接受达格列净和盐酸二甲双胍治疗的2型糖尿病成人患者改善血糖控制。复杂的用药方案导致患者用药依从性差是2型糖尿病患者血糖控制不佳的重要原因之一。达格列净二甲双胍缓释片结合了两种作用机制互补的抗高血糖药物，为改善2型糖尿病患者的血糖控制提供了一线治疗选择。声明：以上内容为企业新闻，不用于任何推广目的。内部审批号: CN-174027 参考文献： 1）Zhang Q, et al. Clin Transl Med. 2022 Feb;12(2):e710. 2）Wang YA, et al.BMC Cancer.2018 Mar 22;18(1):315.

临床3期上市批准申请上市

2025-12-04

·北京医学感染与传染研究

抗菌化疗杂志 80卷 7-12期、增刊2、4期

Journal of Antimicrobial Chemotherapy Volume 80, Issue 7抗菌化疗杂志 80卷 7期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 The role of antimicrobial prophylaxis in brachytherapy for prostate, breast and gynaecological cancer: a narrative review 抗生素预防用药在前列腺、乳腺及妇科癌症近距离治疗中的作用：叙述性综述 Konstantinos Alexakis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1753–1771, 2 To be or not to be: the non-antimicrobial properties of common antimicrobials 生存还是毁灭：常见抗菌药物的非抗菌特性 Shivakumar Narayanan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1772–1783, SYSTEMATIC REVIEWS（系统综述） 3 Antibiotic-induced Bartter-like syndrome: a systematic review 抗生素诱发的巴特综合征样表现：系统综述 Megha Priyadarshi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1784–1791, 4 Liposomal amphotericin B prophylaxis in paediatrics: a systematic review 两性霉素B脂质体预防性用药在儿科中的应用：系统综述 Emma V Thorley and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1792–1802, ORIGINAL RESEARCH（论著） 5 Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study 婴儿期呼吸道合胞病毒感染所致抗生素使用情况——一项国际前瞻性出生队列研究 Sarah F Hak and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1803–1812, 6 Plasmodium falciparum isolates: ex vivo drug response 恶性疟原虫分离株：体外药物反应 Edem Adika and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1813–1822, 7 Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia 低白蛋白血症对接受厄他培南联合疗法治疗甲氧西林敏感金黄色葡萄球菌菌血症患者的影响 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1823–1827, 8 Exploring community pharmacy professionals and general practitioners’ views on primary care communication and pathways to access antibiotics in England 探究英国社区药房专业人员和全科医生对初级保健沟通及获取抗生素途径的看法 Ming Xuan Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1828–1836, 9 Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study 新冠疫情后铜绿假单胞菌菌血症抗菌药物耐药性的下降：一项纵向观察研究 Yulia Butscheid and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1837–1848, 10 Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy 意大利HIV感染者（HIV-RNA不可检测）特定合并症与抗逆转录病毒药物转换概率：一项回顾性分析 Alessandro Cozzi-Lepri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1849–1859, 11 Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time–kill experiments to a mouse pneumonia model 基于模型转化利奈唑胺和万古霉素对甲氧西林耐药金黄色葡萄球菌的药代动力学-药效学关系：从体外时间杀菌实验到小鼠肺炎模型 Diego Vera-Yunca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1860–1868, 12 Inner-mitochondrial membrane protein PfMPV17 is linked to P. falciparum in vitro resistance to the indoloquinolizidine alkaloid alstonine 线粒体内膜蛋白PfMPV17与恶性疟原虫对吲哚醌啉生物碱阿尔斯通宁的体外耐药性相关 J R Macdonald and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1869–1877, 13 Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium 米诺环素与甲硝唑联合治疗大环内酯类耐药生殖支原体感染的疗效和耐受性 Kay Htaik and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1878–1884, 14 Early use of the novel antifungal rezafungin: a case series and literature review 新型抗真菌药物瑞扎芬净的早期使用：病例系列报道及文献综述 H C Davidson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1885–1892, 15 Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach 基于群体药代动力学-药效学模型方法确定阿莫西林在肥胖和胃旁路术后患者中的最佳剂量 Gisela Myrian de Lima Leite Dalla Rosa and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1893–1901, 16 Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade 过去十年，英国代表性家畜物种抗菌药物耐药性下降与抗菌药物总销量减少相关 Aliya El Nagar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1902–1906, 17 An improved multiplex RT–quantitative PCR assay can reveal sex-specific activity of transmission-blocking drugs on ex vivo gametocytes from Plasmodium falciparum asymptomatic infections 一种改进的多重逆转录定量聚合酶链反应检测法可揭示性特异性抗疟疾传播阻断药物对恶性疟原虫无症状感染体外配子体活性的影响 Mariagrazia Ciardo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1907–1914, 18 Population pharmacokinetics and thrombocytopenia risk assessment of linezolid in liver transplant recipients 利奈唑胺在肝移植受者中的群体药代动力学及血小板减少症风险评估 Xiaoping Shi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1915–1925, 19 Rapid susceptibility testing on urine for antimicrobial stewardship in general practice 全科实践中的尿液快速药敏试验助力抗菌药物管理 Patrick D J Sturm and Tanja Schülin Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1926–1932, 20 Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains 利奈唑胺单药治疗每12小时一次与每8小时一次，以及与达托霉素联合治疗甲氧西林耐药和糖肽中介金黄色葡萄球菌菌株所致实验性心内膜炎的疗效 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1933–1941, 21 In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains 新型作用机制抗菌药物NOSO-502对包括多重耐药菌株在内的肠杆菌科临床菌株的体外活性 Marie L G Attwood and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1942–1946, 22 Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions 中性及弱酸性条件下，丙二醇对金黄色葡萄球菌和表皮葡萄球菌的抗菌活性 Nadiia Mosiichuk and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1947–1950, 23 Molecular characteristics of chromosome-mediated colistin resistance in foodborne Salmonella isolates in China 中国食源性沙门氏菌分离株染色体介导的多粘菌素耐药性的分子特征 Zeqiang Zhan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1951–1963, 24 High azole non-wild type rates and nosocomial microsatellite typing aggregation of Wickerhamomyces anomalus in China according to a 12-year multicenter surveillance study 根据一项为期12年的多中心监测研究，中国异常威克汉姆酵母属唑类非野生型率高且医院内微卫星分型聚集 Zhengyu Luo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1964–1971, 25 Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus 抗疟药物再利用：乙胺嘧啶对加德纳菌的体外活性优于甲硝唑，且对乳酸杆菌无影响 Aliona S Rosca and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1972–1979, 26 Clinical characteristics and risk factors of tigecycline-induced acute pancreatitis in kidney transplant recipients: a retrospective study 肾移植受者替加环素诱发急性胰腺炎的临床特征及危险因素：一项回顾性研究 Lijuan Feng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1980–1987, 27 Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875 多重耐药鲍曼不动杆菌全球克隆1型参考菌株A297/RUH875的基因组特征 Jonathan Koong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1988–1992, 28 Comparison of a modified broth microdilution Sensititre™ SLOMYCOI assay with the CLSI-recommended agar disk elution method for antimicrobial susceptibility testing of Mycobacterium haemophilum 改良肉汤微量稀释Sensititre™ SLOMYCOI检测法与CLSI推荐的琼脂稀释法对嗜血杆菌属抗菌药物敏感性检测的比较 Doris Hillemann and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1993–1996, 29 Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations 由于细菌噬菌体和抗生素在临床可达到浓度下的体外协同作用，多重耐药碳青霉烯酶产生肺炎克雷伯菌临床分离株的表型耐药性发生逆转 Paschalis Paranos and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 1997–2006, 30 Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France 瑞典和法国假体关节感染表皮葡萄球菌的抗生素耐药性和群体结构 Sofie M Edslev and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2007–2015, 31 Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections 抗生素锁疗法与导管拔除术治疗中心血管导管感染的影响评估 Nischal Ranganath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2016–2024, 32 Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control 肺炎克雷伯菌实时傅里叶变换红外分型：一种灵活快速的暴发检测和感染控制方法 Ana Beatriz Gonçalves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2025–2031, 33 Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori 抗生素压力影响幽门螺杆菌产生的细胞外囊泡的分泌和物理化学特性 Paweł Krzyżek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2032–2043, 34 A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro 生殖支原体体外诱导产生的新型阿奇霉素耐药突变 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2044–2050, RESEARCH LETTERS（研究信函） 35 Posaconazole dosing of enteral formulations in infants and young children to achieve therapeutic concentrations 婴儿和幼儿肠内制剂泊沙康唑的给药剂量以达到治疗浓度 Jeffrey Harrington and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2051–2053, 36 Antimony used as rescue therapy in a kidney transplant recipient unresponsive to liposomal amphotericin B for chronic visceral leishmaniasis 两性霉素B脂质体治疗慢性内脏利什曼病无效的肾移植受者中使用锑剂作为挽救疗法 Natacha Mrozek and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2053–2056, 37 Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis? 头孢唑林是否可用于治疗葡萄球菌性内源性眼内炎？ Alexandra Morin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2057–2058, LETTER TO THE EDITOR（致编辑的信） 38 Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre—a counterpoint 单用替考拉宁治疗肠球菌感染性心内膜炎：一家转诊中心的回顾性和比较研究——反驳观点 Miguel Villamarín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 7, July 2025, Pages 2059–2060, Journal of Antimicrobial Chemotherapy Volume 80, Issue 8 抗菌化疗杂志 80卷 8期 https://academic.oup.com/jac/issue Review(综述) 1 World Health Organisation’s Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: ‘challenges and opportunities’ 世界卫生组织2017年和2024年用以应对全球抗菌药物耐药性危机的细菌病原体优先名单（BPPL）：“挑战与机遇” Vazhayil Hari Krishnaprasad and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2061–2069 Original Research(论著) 2 Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5years of surveillance prior to approval for clinical use (2019–2023) 氨曲南/阿维巴坦对欧洲医疗中心肠杆菌科细菌的活性：临床批准前5年（2019-2023年）监测总结 Helio S Sader and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2070–2079 3 High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid 利奈唑胺唾液治疗药物监测可行性高，但替地唑胺可行性较低：一项健康受试者单剂量研究和一项接受利奈唑胺患者单中心前瞻性探索性研究 Hitoshi Kawasuji and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2080–2091 4 Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium 缩小版中空纤维感染模型的建立与验证及万古霉素对粪肠球菌的药代动力学/药效学分析 Yukitaka Hayashi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2092–2099 5 Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial 为期4个月的氯法齐明方案治疗敏感型肺结核：一项随机临床试验 Nusrat Shafiq and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2100–2108 6 An ex vivo model to determine transmembrane clearance of antimicrobials during continuous renal replacement therapy 用于确定连续性肾脏替代治疗期间抗菌药物跨膜清除率的体外模型 Cole McGrath and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2109–2116 7 Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa 黏液型铜绿假单胞菌纸片扩散法的优化与改进 Aixin Wang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2117–2125 8 HIV-1 drug resistance among people living with HIV receiving dolutegravir-based anti-retroviral regimens in Uganda: a national laboratory-based survey using remnant viral load samples, 2022 乌干达接受基于多替拉韦抗逆转录病毒方案的HIV感染者中HIV-1耐药性情况：2022年一项基于国家实验室使用剩余病毒载量样本的调查 Christine Watera and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2126–2134 9 Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women 与固定剂量相比，基于体重给药的CAP256V2LS（一种用于女性HIV预防的广谱中和抗体）群体药代动力学研究 Sharana Mahomed and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2135–2144 10 Gut microbiota and weight gain in people with HIV on integrase inhibitors: a five-year longitudinal study 接受整合酶抑制剂治疗的HIV感染者肠道微生物群与体重增加情况：一项为期五年的纵向研究 Javier García-Abellán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2145–2157 11 Development of a ribavirin dosing regimen in transplant recipients with chronic hepatitis E virus infection: a population pharmacokinetic and -dynamic model 慢性戊型肝炎病毒感染移植受者利巴韦林给药方案的开发：一项群体药代动力学和药效学模型研究 Midas B Mulder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2158–2168 12 Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort 长效卡博特韦/利匹韦林在病毒受抑制的HIV感染者中的治疗中断有效性和预测因素：来自Icona队列的现实数据 Roberta Gagliardini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2169–2178 13 Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial 病毒受抑制的HIV感染者中，5天用药2天停药（FOTO）方案与每日比克替拉韦/恩曲他滨/丙酚替诺福韦方案的对比：一项初步随机临床试验 Hsin-Yun Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2179–2186 14 Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia 青霉素敏感金黄色葡萄球菌菌血症的纸片扩散试验可靠性和分子流行病学研究 Pernilla Kihlberg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2187–2193 15 Outcomes of ceftriaxone 2g versus 1g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 住院肺炎患者每日头孢曲松2克与1克疗效对比：一项全国性回顾性队列研究 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2194–2202 16 Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway 齐墩果酸衍生物巴多昔隆通过破坏细胞膜和丙酮酸代谢途径对抗多重耐药金黄色葡萄球菌 Yun-Dan Zheng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2203–2213 17 Evaluation of amoxicillin and benzylpenicillin therapy in early-onset neonatal sepsis: a pharmacometric external validation and simulation study 阿莫西林和苄青霉素治疗早期新生儿败血症的评估：一项药效计量学外部验证和模拟研究 Tom C Zwart and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2214–2225 18 48Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trial HIV感染者换用多替拉韦加拉米夫定治疗48周身体成分变化：DOLAM随机临床试验的计划子分析 Elisa de Lazzari and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2226–2233 19 The impact of inter-infection time on antimicrobial resistance profiles in women with multiple urinary tract infections over time 多次尿路感染女性患者感染间隔时间对抗菌药物耐药性特征的影响 Trenton Honda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2234–2240 20 Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales 一种检测产DHA肠杆菌科细菌的新型快速免疫层析法的开发与评估 Christian Moguet and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2241–2246 21 Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes 粪肠球菌菌血症：一项关注临床和微生物学结局风险因素的多中心观察性研究 Matteo Rinaldi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2247–2256 22 Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus 靛红咔唑类化合物作为宿主导向疗法对抗甲氧西林耐药金黄色葡萄球菌细胞内感染 Robin H G A van den Biggelaar and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2257–2268 23 Clinical validation of antimicrobial dosing regimens for continuous renal replacement therapy based on an ex vivo dosing algorithm 基于体外给药算法的连续性肾脏替代治疗抗菌药物给药方案的临床验证 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2269–2279 24 Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy 意大利牛犊艰难梭菌分离株中携带cfr(B)和cfr(C)利奈唑胺耐药基因的新型整合性和接合性元件 Andrea Brenciani and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2280–2284 25 Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015–2022 2015-2022年从撒哈拉以南非洲返回的法国患者中分离出的产碳青霉烯酶肠杆菌科细菌的特征 Corentin Poignon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2285–2294 26 Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections 具有强生物膜形成能力的青霉素敏感ST398型对骨关节感染构成重大威胁 Ye Jin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2295–2304 27 Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB 贝达喹啉、德拉马尼和莫西沙星与不同剂量苏特唑利或德帕唑利联合用药治疗药物敏感型肺结核的心脏安全性 Simon E Koele and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2305–2313 28 Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study 头孢托唑坦/他唑巴坦与美罗培南治疗产超广谱β-内酰胺酶肠杆菌科细菌所致血流感染的对比：一项单中心回顾性现实研究 Dimitrios Basoulis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2314–2322 Research Letters(研究信件) 29 Dalbavancin as chronic suppressive therapy in a patient undergoing monthly apheresis: a case report with therapeutic drug monitoring 达巴万星作为每月进行血浆置换术患者的长期抑制治疗：一项带治疗药物监测的病例报告 Carlo Pallotto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2323–2324 30 A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs 韩国猪体内发现的一种带有未表征SCCmec变体的新型甲氧西林耐药金黄色葡萄球菌谱系（ST4174） Hyeonwoo Cho and Kun Taek Park Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2325–2326 31 Time fixes everything, but not always: 10years of persistent PI mutations in the absence of pharmacological pressure—a case report 时间能治愈一切，但并非总是如此：无药物压力下持续10年的蛋白酶抑制剂突变——一例病例报告 Layla Pagnucco and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2327–2330 32 Carbapenem resistance in Escherichia marmotae: characterization of IncL plasmids carrying blaOXA-48 土拨鼠埃希菌的碳青霉烯耐药性：携带blaOXA-48的IncL质粒特征 Astrid Rasmussen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2330–2331 Letters to the Editor(致编辑的信) 33 Comment on: Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital 述评：产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究 Jianjun Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2332 34 Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a Tertiary University Hospital—right to reply—author’s response 产碳青霉烯酶肠杆菌科细菌血流感染患儿的临床预后和治疗方式的影响：一项来自三级大学医院的回顾性队列研究——作者回复 Gulhadiye Avcu Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Pages 2332–2333 Corrections(更正) 35 Correction to: Sofosbuvir as post-exposure prophylaxis for yellow fever–associated viscerotropic disease (YEL-AVD) 更正：索非布韦作为黄热病相关内脏热带病（YEL-AVD）暴露后预防用药 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2334 36 Correction to: Pandemic human-associated extended-spectrum β-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs 更正：维也纳犬体内发现与人相关的大流行性产超广谱β-内酰胺酶大肠杆菌ST38、ST131和ST141谱系 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2335 37 Correction to: GP or ChatGPT? Ability of large language models (LLMs) to support general practitioners when prescribing antibiotics 更正：全科医生还是ChatGPT？大型语言模型（LLM）在全科医生开具抗生素处方时的辅助能力 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 8, August 2025, Page 2336 Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2 抗菌化疗杂志 80卷增刊2期 https://academic.oup.com/jac/issue SUPPLEMENT (补充) CANWARD 2007-23 加拿大抗感染耐药监测项目（CANWARD）2007-2023年数据/报告 Foreword(前言) 1 The CANWARD studies: Canadian Antimicrobial Resistance Alliance (CARA) Canadian Hospital Ward Antibiotic Resistance Surveillance collection 加拿大抗感染耐药监测项目研究：加拿大抗微生物耐药联盟（CARA）加拿大医院病房耐药性监测数据集 James C Hurley and Jean-Yves Madec Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Page ii1 Supplement Papers(补充论文) 2 Seventeen years of the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究17年（2007-2023年） George G Zhanel and Heather J Adam Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii2–ii4 3 Gram-positive pathogens from Canadian hospitals: 17years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阳性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii5–ii14 4 Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007–23) 来自加拿大医院的革兰氏阴性病原体：加拿大抗感染耐药监测项目研究的17年结果（2007-2023） George G Zhanel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii15–ii26 5 Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐甲氧西林金黄色葡萄球菌的特征：加拿大抗感染耐药监测项目研究的17年（2007-2023） Anissa Brahami and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii27–ii34 6 Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007–23) 加拿大抗感染耐药监测项目研究中加拿大医院血液培养和呼吸道标本中肺炎链球菌抗微生物药物耐药性和血清型的比较（2007-23） Heather J Adam and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii35–ii44 7 Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23 加拿大医院中产生ESBL的大肠杆菌和肺炎克雷伯菌的比率增加：加拿大抗感染耐药监测项目研究17年，2007-2023 Philippe Lagacé-Wiens and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii45–ii53 8 Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007–23) 加拿大医院耐厄他培宁肠杆菌的特征：17年的加拿大抗感染耐药监测项目研究（2007-23） Laura F Mataseje and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii54–ii61 9 Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6years of the CANWARD study (2018–23) 加拿大医院耐碳青霉烯假单胞菌的特征：6年的加拿大抗感染耐药监测项目研究（2018-23） Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii62–ii71 10 Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007–23) 加拿大患者血液中病原菌的分布和药敏特征：来自加拿大抗感染耐药监测项目研究（2007-23）的结果 Andrew Walkty and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_2, September 2025, Pages ii72–ii82 Journal of Antimicrobial Chemotherapy Volume 80, Issue 9抗菌化疗杂志 80卷 9期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Classifying patients with invasive fungal disease: towards a unified case definition? 侵袭性真菌病患者分类：能否达成统一的病例定义？ Mehmet Ergün and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2337–2343, SYSTEMATIC REVIEW（系统综述） 2 Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis 早期转换为口服抗生素治疗革兰氏阳性菌血流感染的疗效和安全性：一项系统综述和荟萃分析 ZhaoYi Tan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2344–2360, ORIGINAL RESEARCH（论著） 3 Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium 屎肠球菌中那拉霉素、盐霉素、拉沙洛西钠和莫能菌素流行病学临界值的测定 Maria Laura Ferrando and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2361–2368, 4 Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 四类耐药HIV感染者体内CXCR4嗜性病毒的持续存在及其在现代抗逆转录病毒治疗时代的临床影响 Rebecka Papaioannu Borjesson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2369–2374, 5 Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks 随机试验中96周内使用多替拉韦或对照抗逆转录病毒疗法对高血压和血压变化的影响 Parul Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2375–2383, 6 Comparative analysis of lipid profile changes in treatment-naïve people living with HIV on INSTI-based single-tablet regimens, BIC/FTC/TAF and DTG/3TC: real-world evidence from South Korea 基于整合酶抑制剂的单片复方制剂BIC/FTC/TAF和DTG/3TC在韩国初治HIV感染者中血脂谱变化的比较分析：来自现实世界的证据 So Yun Lim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2384–2390, 7 A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme 摩根氏菌属的一种新型多位点序列分型方案：群体结构及引入用于标准化多位点序列分型方案的定量度量标准 Aymeric Jacquemin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2391–2398, 8 Genomic characterization of multidrug-resistant extended-spectrum β-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya 2022年肯尼亚霍乱疫情中产超广谱β-内酰胺酶的多重耐药霍乱弧菌O1株的基因组特征 Diana Imoli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2399–2407, 9 Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection 经验性抗万古霉素耐药肠球菌治疗对万古霉素耐药肠球菌血流感染患者生存率的影响 Tao-Hung Ou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2408–2416, 10 Safety of topical tobramycin powder during operative treatment of fractures 骨折手术中使用局部妥布霉素粉末的安全性 Gregory M Schrank and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2417–2420, 11 Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS 复方磺胺甲恶唑与噬血细胞性淋巴组织细胞增多症（HLH）的风险：基于FAERS数据库个案安全报告的文献综述和比例失衡分析 Rinko Lau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2421–2427, 12 Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England 从返回英国的旅行者中分离出携带blaPER-7基因的高度耐药霍乱弧菌 Satheesh Nair and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2428–2432, 13 Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics 克服幽门螺杆菌的抗菌药物耐药性：附带敏感性和生物膜动态的作用 Siddharth Singh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2433–2441, 14 Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 四种未接触过但对头孢地尔耐药的产NDM肺炎克雷伯菌所致血流感染的临床和微生物学分析 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2442–2446, 15 Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo DHA27与庆大霉素联合对耐甲氧西林金黄色葡萄球菌的体内外协同作用 Xuemin Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2447–2458, 16 A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology 采用EUCAST肉汤微量稀释参考方法进行耳念珠菌流行病学临界值的多中心测定研究 Joseph Meletiadis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2459–2465, 17 Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study 万古霉素耐药对屎肠球菌血流感染归因死亡率的影响：一项大型多中心回顾性研究的倾向评分分析 M Del Monte and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2466–2473, 18 Dynamics of dual CMV and EBV co-reactivation and emergence of resistance in an HSCT recipient 异基因造血干细胞移植受者中CMV和EBV双重再激活的动态变化及耐药性的出现 Martyna Pociupany and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2474–2483, 19 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2484–2486, 20 Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database 使用经验性哌拉西林/他唑巴坦和头孢吡肟的脓毒症患者死亡率比较：基于MIMIC-IV数据库的分析 Yongseop Lee and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2487–2495, 21 Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024 2024年中国河南省HIV-1感染者传播耐药情况 Jinjin Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2496–2502, 22 Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance A类碳青霉烯酶基因blaFRI拷贝数的波动似乎赋予了高水平碳青霉烯耐药性 Makiko Noda and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2503–2512, 23 In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization 头孢比罗联合氨苄西林对引起感染性心内膜炎的粪肠球菌的体外活性：表型和基因型特征 Clara Moretó-Castellsaguéand others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2513–2523, 24 Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates 达巴万星与β-内酰胺类药物对心内膜炎相关粪肠球菌临床分离株的矛盾相互作用 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2524–2529, 25 Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation 伯克霍尔德菌复合群药敏试验中肉汤微量稀释法和梯度扩散法的比较评估：向基于ECV解释转变的影响 Wenjie Cui and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2530–2540, 26 Strengthening antimicrobial resistance diagnostics in National Reference Laboratories across One Health in South and Southeast Asia: impact of external quality assessment and targeted follow-up 加强南亚和东南亚“同一健康”国家参考实验室的抗菌药物耐药性诊断能力：外部质量评估和针对性随访的影响 Freshwork Ayalew Abegaz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2541–2549, RESEARCH LETTERS（研究快信） 27 TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient 治疗药物监测指导下的美罗培南/瓦博巴坦疗法成功治疗儿童肝移植受者中产KPC且对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌引起的腹腔和血流感染 Giovanni Mulé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2550–2552, 28 Novel tmexC7D2-toprJ5 gene cluster and transposon Tn7759 carrying blaVIM-2 and blaOXA-10 genes in a carbapenem-resistant Pseudomonas putida from urban sewage 城市污水中碳青霉烯耐药恶臭假单胞菌中携带blaVIM-2和blaOXA-10基因的新型tmexC7D2-toprJ5基因簇和转座子Tn7759 Xinyuan Qiu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2552–2555, 29 Characterization of multiresistance gene optrA in Bacillus subtillis from China 中国枯草芽孢杆菌中多重耐药基因optrA的特征分析 Yongliang Che and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2555–2557, 30 Genomic characterization of a multidrug-resistant Mammaliicoccus sciuri strain isolated from urine of a patient from China 从中国患者尿液中分离出的一株多重耐药马氏鼠球菌的基因组特征 Fuqiang Ye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2558–2560, LETTERS TO THE EDITOR（致编辑的信） 31 Comment on: Isavuconazole therapeutic drug monitoring and association with adverse events 关于“艾沙康唑治疗药物监测及其与不良反应的关联”的评论 Mi Zhou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2561–2562, 32 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalised patients with pneumonia: a nationwide retrospective cohort study 关于“住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究”的评论 Satoru Mitsuboshi Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Page 2563, 33 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—authors’ response 住院肺炎患者每日2克与1克头孢曲松疗效比较：一项全国性回顾性队列研究——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 9, September 2025, Pages 2563–2564, Journal of Antimicrobial Chemotherapy Volume 80, Issue 10抗菌化疗杂志 80卷 10期 https://academic.oup.com/jac/issue REVIEWS（综述） 1 Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead 长效卡博特韦和利匹韦林治疗HIV感染者的现状与未来挑战 Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2565–2586, 2 Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 系统综述与《抗菌化疗杂志》：过去、现在与未来——系统再评估 James C Hurley Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2587–2596, SYSTEMATIC REVIEWS（系统综述） 3 Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology 研究肺结核治疗的肺内药代动力学：方法学的系统综述 Isabella van der Feltz and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2597–2608, 4 Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis 全球人类中耐呋喃妥因的尿路致病性大肠埃希菌（UPEC）流行率：系统综述与荟萃分析 Christopher Larkin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2609–2621, ORIGINAL RESEARCH（研究论著） 5 Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium? 氨苄青霉素联合头孢菌素是否为氨苄青霉素敏感的粪肠球菌的治疗选择？ Paula Bierge and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2622–2629, 6 Therapeutic efficacy monitoring of pyronaridine–artesunate (Pyramax®) in treating uncomplicated Plasmodium falciparum malaria in Gia Lai province, Vietnam from 2022 to 2023 2022-2023年越南嘉莱省青蒿琥酯-吡咯尼抗（Pyramax®）用于无并发症恶性疟原虫疟疾的治疗效果监测 Nguyen Van Thanh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2630–2634, 7 Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia 哌拉西林/他唑巴坦负荷剂量用于革兰氏阴性菌血症患者延长输注给药的有效性 Savan Patel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2635–2643, 8 Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia 连续输注大剂量头孢比罗在社区获得性肺炎危重患者中的肺内浓度 Claire Roger and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2644–2653, 9 Cefixime versus benzathine penicillin G for the treatment of early syphilis—a randomized, controlled open label trial 头孢克肟与苄星青霉素G治疗早期梅毒的随机对照开放标签试验 Tamara Klementová and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2654–2658, 10 Trends in antifungal use among hospitalized patients in the USA, 2018–23 2018-2023年美国住院患者抗真菌药物使用趋势 Dallas J Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2659–2664, 11 Clinical impact of the BCID2 and rapid AST VITEK® REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study BCID2和快速AST VITEK® REVEALTM对革兰氏阴性菌血流感染危重患者抗生素优化的临床影响：一项准实验性前后干预研究 Louis Oudiane and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2665–2675, 12 In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium 甲砜霉素对药物敏感和耐药生殖支原体菌株的体外活性 Sofie Skovmand and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2676–2681, 13 A priori optimization of levofloxacin dose regimen based on a population pharmacokinetics model 基于群体药代动力学模型的左氧氟沙星剂量方案先验优化 Emmanuel Enard and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2682–2692, 14 Model-informed individualized administration of ceftazidime–avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis 危重患者头孢他啶-阿维巴坦的模型知情个体化给药：群体药代动力学研究和参数时间事件分析 Tingting Wu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2693–2704, 15 Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria 开发血培养阳性时间作为监测针对多重耐药革兰氏阴性菌抗生素治疗的药效动力学指标 Irene Zaghi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2705–2713, 16 In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model 头孢布坦-莱达博巴坦口服联合用药对产丝氨酸-β-内酰胺酶肠杆菌科细菌的体内活性评估：在肾盂肾炎和膀胱炎小鼠模型中的评估 Christina Koenig and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2714–2718, 17 Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial 健康受试者静脉注射后口服奥马环素的粪便药代动力学、微生物组和胆汁酸变化：一项1期临床试验 Jinhee Jo and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2719–2726, 18 Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application 抗逆转录病毒治疗依从性干血斑检测法的实验室间比对：对临床应用的启示 Nathan Engel and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2727–2731, 19 A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study 意大利北部长效注射用卡博特韦和利匹韦林有效性、持久性和安全性的现实中多中心前瞻性队列研究：LONGITUDE研究 Maria Mazzitelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2732–2741, 20 Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study 使用白蛋白-胆红素评分和纤维化-4指数评估头孢吡肟诱导的肝酶水平异常发生风险：一项单中心回顾性病例对照研究 Hiroki Katsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2742–2751, 21 Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial BALANCE临床试验中血流感染患者的临床病程 Sean W X Ong and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2752–2758, 22 Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study 神经重症患者中多黏菌素治疗碳青霉烯类耐药革兰氏阴性菌肺炎的结果比较：一项回顾性队列研究 Qian Zeng and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2759–2772, 23 Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 肉鸡和人类临床分离的粪肠球菌中NarAB的不同群体结构和基因组背景 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2773–2781, 24 Population pharmacokinetics of bictegravir in real-world people with HIV 现实中HIV感染者比克替拉韦的群体药代动力学 Pierre Ekobena and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2782–2789, 25 Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index 活动性肺结核整个治疗期间利福平浓度：性别和体重指数的影响 Teres Samuelsson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2790–2798, 26 Performance of disc diffusion and gradient strip test on different Mueller–Hinton agar media plates and ComASP® and Bruker UMIC® Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa 在碳青霉烯类耐药铜绿假单胞菌中对头孢地尔敏感性测试使用不同穆勒-欣顿琼脂培养基平板和ComASP®及Bruker UMIC®头孢地尔微量稀释板的纸片扩散法和梯度条带测试的性能 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2799–2806, 27 Placental transfer of medications to treat COVID-19, molnupiravir, favipiravir and nirmatrelvir/ritonavir, in the ex vivo human cotyledon model 在离体人类绒毛叶模型中治疗COVID-19的药物莫努匹拉韦、法维拉韦和奈玛特韦/利托那韦的胎盘转移 Solene Labaye and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2807–2813, 28 Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms 针对具有多种耐药机制的高度耐药鲍曼不动杆菌患者分离株的含头孢地尔抗生素联合用药的协同作用 Justin Halim and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2814–2824, 29 Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015–22: experience from an HIV clinic in Paris, France 2015-2022年药物减量抗逆转录病毒策略的采用情况及对成本的影响：来自法国巴黎一家HIV诊所的经验 L Sagaon-Teyssier and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2825–2833, 30 Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin 对达拉氟沙星敏感的侵袭性临床肺炎链球菌分离株中氟喹诺酮耐药性的分子特征 Emilia Cercenado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2834–2843, 31 Genomic structure of class 1 and 2 integrons in non-typhoidal Salmonella isolated from food animals and related meat products in the USA 美国食品动物及其相关肉类产品中分离的非伤寒沙门氏菌1类和2类整合子的基因组结构 Chih-Hao Hsu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2844–2853, 32 Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii 鲍曼不动杆菌中blaOXA-542介导的碳青霉烯类耐药性的特征 Jingchen Hao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2854–2861, 33 Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones 各种诺卡氏菌属临床分离株对碳青霉烯类和氟喹诺酮类的表型和基因型特征 Jing Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2862–2872, RESEARCH LETTERS（研究快报） 34 Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? 奥利他万星治疗粪肠球菌复发性心内膜炎患者：一种新的治疗选择？ Giulia Turicchi and Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2873–2874, 35 The catA1 chloramphenicol resistance gene originated in Atlantibacter hermannii catA1氯霉素耐药基因起源于大西洋菌属赫尔曼尼菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2874–2876, 36 Horizontal transmission of a multidrug-resistant IncM1 plasmid harbouring blaOXA-48 and blaCTX-M-14b among patient microbiotas 携带blaOXA-48和blaCTX-M-14b的多重耐药IncM1质粒在患者微生物群中的水平传播 Roberto Sierra and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2876–2879, 37 Antimicrobial activity of temocillin on ceftriaxone-resistant and ceftriaxone-susceptible isolates of Neisseria gonorrhoeae 替莫西林对头孢曲松耐药和头孢曲松敏感淋病奈瑟菌分离株的抗菌活性 Julie Brousseau and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2879–2881, LETTERS TO THE EDITOR（致编辑的信） 38 Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus 述评：抗生素联合用药对临床分离的鸡肠球菌和粪肠球菌的杀菌活性 Karl Oldberg and Magnus Rasmussen Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2882–2883, 39 Comment on: Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study 述评：住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究 Giancarlo Ceccarelli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2884–2885, 40 Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study—right to reply—authors’ response 住院肺炎患者每日2克与1克头孢曲松的疗效：一项全国性回顾性队列研究——作者回应权——作者回复 Jumpei Taniguchi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10, October 2025, Pages 2885–2886, Journal of Antimicrobial Chemotherapy Volume 80, Issue Supplement_4抗菌化疗杂志 80卷增刊4期 https://academic.oup.com/jac/issue/80/Supplement_4 SUPPLEMENT（补充） Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 FOREWORD（前言） 1 Two Decades of BSAC Resistance Surveillance 英国抗菌化疗学会二十年耐药性监测 James C Hurley and Alan P Johnson Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Page iv1, SUPPLEMENT PAPERS（补充论文） 2 Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions 英国抗菌化疗学会二十年耐药性监测：设计、发展、实施、不足与未来方向 Alasdair P MacGowan and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv2–iv6, 3 The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations 英国抗菌化疗学会耐药性监测项目：方法与局限性 Michael Allen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv7–iv21, 4 Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阳性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv22–iv35, 5 Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019 英国和爱尔兰地区革兰氏阴性菌血流感染病原体的抗菌药物耐药性趋势（2001 - 2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv36–iv48, 6 Antimicrobial resistance among agents of hospital-acquired lower respiratory tract infection in the UK and Ireland: trends from 2008/2009 to 2018/2019 英国和爱尔兰地区医院获得性下呼吸道感染病原体的抗菌药物耐药性趋势（2008/2009 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv49–iv59, 7 Antimicrobial resistance among agents of community-associated lower respiratory tract infection in the UK and Ireland: trends from 1999/2000 to 2018/2019 英国和爱尔兰地区社区获得性下呼吸道感染病原体的抗菌药物耐药性趋势（1999/2000 - 2018/2019年） Rosy Reynolds and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv60–iv71, 8 Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999–2019) 英国和爱尔兰地区肺炎链球菌血清型及耐药性趋势（1999 - 2019年） Carolyne Horner and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv72–iv86, 9 Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project—legacy and future 英国抗菌化疗学会耐药性监测项目的应用与益处——成果与未来 Benjamin J Parcell and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue Supplement_4, October 2025, Pages iv87–iv95, Journal of Antimicrobial Chemotherapy Volume 80, Issue 11抗菌化疗杂志 80卷 11期 https://academic.oup.com/jac/issue VIEWPOINTS（观点） 1 Modification of antimicrobial susceptibility testing methods 抗菌药物敏感性检测方法的修改 Ian Morrissey and Jean B Patel Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2887–2888, 2 Viewpoint: global antimicrobial stewardship accreditation is needed: the experience in Kentucky, USA 观点：需要建立全球抗菌药物管理认证体系：美国肯塔基州的经验 Ashley M Wilde and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2889–2891, REVIEWS（综述） 3 Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules 噬菌体揭示抗菌药物耐药性的生物学脉络：从起源与传播到替代治疗模式 Cleo Anastassopoulou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2892–2901, 4 Molecular drivers of fusion plasmid: mechanistic insights and evolutionary implications 融合质粒的分子驱动因素：机制见解与进化意义 Ziyi Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2902–2911, ORIGINAL RESEARCH（研究论著） 5 Emergence of livestock-associated MRSA clonal complex 398 in Thailand’s swine industry 泰国养猪业中出现与牲畜相关的MRSA克隆复合体398 Pawarut Narongpun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2912–2917, 6 Peripheral neuropathy during long-term suppressive therapy with tedizolid: a case series 长期使用替达拉韦抑制治疗期间出现周围神经病变：系列病例报告 Tomaso Beringheli and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2918–2922, 7 Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections 细菌低代谢作为抗菌药物耐药性的核心机制及心室辅助装置驱动线感染中葡萄球菌生物膜的潜在治疗靶点 Yao Sun and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2923–2933, 8 The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus acnA在连接碳代谢与耐甲氧西林金黄色葡萄球菌的毒力和抗菌药物耐药性中的关键作用 Jiahui Li and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2934–2944, 9 Pharmacokinetics of rifampicin and isoniazid in patients with HIV–tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292–RIFAVIRENZ sub-study 接受以依非韦伦为基础的抗逆转录病毒治疗的HIV-结核病共感染患者中利福平和异烟肼的药代动力学：ANRS12292-RIFAVIRENZ子研究 Thibaut Gelé and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2945–2953, 10 Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare 胞内分枝杆菌中与氯法齐明耐药相关的新型突变 Xiuzhi Jiang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2954–2957, 11 Physiologically informed in vitro framework reveals context-dependent combinatory activity of niclosamide–colistin against Gram-negative bacteria 基于生理信息的体外框架揭示了针对革兰氏阴性菌的硝基咪唑-多粘菌素组合的情境依赖性活性 Mariana Romero-Gonzalez and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2958–2969, 12 In vitro evolution provides insights into mechanisms of Mycoplasma genitalium resistance to moxifloxacin 体外进化揭示生殖支原体对莫西沙星的耐药机制 Teck-Phui Chua and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2970–2977, 13 The toxin–antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening 毒素-抗毒素系统SavRS通过介导细胞壁增厚促进万古霉素中间型金黄色葡萄球菌对万古霉素的耐药性 Weifeng Xu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2978–2988, 14 Molecular insights into carbapenemase-producing Enterobacterales from Senegal 塞内加尔产碳青霉烯酶肠杆菌目细菌的分子特征 Ousmane Sow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 2989–3000, 15 Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients 老年患者中利奈唑胺及其代谢产物PNU-142300的群体药代动力学模型 Xianglong Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3001–3010, 16 In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China 在中国开展的一项多中心研究中，康替唑胺及其他对照药物对临床分离的金黄色葡萄球菌和肠球菌的体外活性 Rongqi Lu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3011–3020, 17 Co-existence of the oxazolidinone resistance genes cfr and optrA on a novel multiresistance plasmid from a methicillin-resistant Macrococcoides bohemicum strain 从一株耐甲氧西林的马科考代菌属波希米亚菌株中发现的携带恶唑烷酮耐药基因cfr和optrA的新型多重耐药质粒 Yao Zhu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3021–3025, 18 Multidrug resistance and recurrence in urinary bacteraemia among cancer patients 癌症患者中尿路菌血症的多药耐药性和复发情况 Ignacio Grafia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3026–3033, 19 Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection 在严重的体内感染期间，ST11型碳青霉烯耐药且高毒力的肺炎克雷伯菌中blaKPC变体的快速替代导致头孢他啶/阿维巴坦耐药 Ping Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3034–3042, 20 Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals 伴侣动物中碳青霉烯类不敏感铜绿假单胞菌对人类健康的潜在风险 Jirachaya Toyting-Hiraishi and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3043–3056, 21 Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales 液相色谱-串联质谱（LC-MS/MS）工具在检测肠杆菌目细菌抗菌药物耐药机制中的应用评估 Anna Witkowska and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3057–3064, 22 Multidrug efflux pumps and innate azole resistance of Mucor lusitanicus 毛霉属葡萄牙菌的多药外排泵及其固有唑类耐药性 Stephanie Toepfer and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3065–3078, 23 Ivermectin dosing for children under 2 years 2岁以下儿童的伊维菌素剂量 Wenyu Yang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3079–3081, 24 Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort 一线拉米夫定/多替拉韦抗逆转录病毒疗法在HIV感染者中的有效性：来自ICONA基金会队列的现实数据 Alessandra Vergori and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3082–3091, 25 Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic 城市学术型HIV诊所中长效注射用卡博特韦-利匹韦林启动的资格及关联因素 Geoffroy Liegeon and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3092–3100, 26 Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 在接受抑制性抗逆转录病毒治疗的高度治疗经验丰富和多药耐药个体中，HIV-1 DNA耐药演变的评估：来自PRESTIGIO登记处的纵向研究 D Armenia and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3101–3106, 27 Sequential antibiotic exposure restores antibiotic susceptibility 序贯抗生素暴露恢复抗生素敏感性 Farhan R Chowdhury and Brandon L Findlay Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3107–3117, 28 Dermatological adverse effects of doxycycline as post-exposure prophylaxis for sexually transmitted infections among men who have sex with men: real-world findings from a multicentre study 在男男性行为者中，使用多西环素作为性传播感染暴露后预防的皮肤科不良反应：一项多中心研究的现实发现 Ling-Ya Chen and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3118–3122, 29 Phenotype–genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt 埃及导管相关尿路感染中分离的革兰氏阴性尿路病原菌抗菌药物耐药性表型-基因型不一致性 Mohamed Eladawy and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3123–3132, 30 How should APOBEC3-induced resistance mutations be considered in the management of antiretroviral therapy? 在抗逆转录病毒治疗管理中，应如何考虑APOBEC3诱导的耐药突变？ Marie Gilbert and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3133–3138, 31 In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species 奥洛芬和抗真菌药物组合对曲霉菌和念珠菌属的体外评价 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3139–3149, 32 Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis 在侵袭性肺曲霉病小鼠模型中，泊沙康唑与奥洛芬之间的拮抗作用 Christopher A Darlow and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3150–3159, 33 High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon 喀麦隆可检测到病毒载量的青少年中HIV-1药物耐药突变的存档和循环水平较高 Armando B D Djiyou and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3160–3164, RESEARCH LETTERS（研究快讯） 34 SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants 新型第二代三萜类抗真菌药物SCY-247对包括FKS1突变体在内的多种基因型耳道假丝酵母菌显示出高体外活性 Bram Spruijtenburg and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3165–3166, 35 Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure? 替西帕肽与抗逆转录病毒药物之间的药物-药物相互作用：是时候重新评估和安心了吗？ Andrea Poloni and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3167–3168, 36 Does the use of topical azoles have an impact on antifungal resistance? 局部使用唑类药物对抗真菌耐药性有影响吗？ Jean-Yves Maillard Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3168–3186, 37 Leakage of cabotegravir and rilpivirine in HIV patients receiving long-acting injectable antiretroviral therapy 接受长效注射用抗逆转录病毒治疗的HIV患者中卡博特韦和利匹韦林的泄漏情况 Samir Benkouiten and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Pages 3187–3188, CORRECTION（更正） 38 Correction to: Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae 更正：对四种产NDM且之前未接触过头孢地洛的耐药肺炎克雷伯菌引起的血流感染的临床和微生物学分析 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 11, November 2025, Page 3189, Journal of Antimicrobial Chemotherapy Volume 80, Issue 12抗菌化疗杂志 80卷 12期 https://academic.oup.com/jac/issue VIEWPOINT（观点） 1 Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying ‘breakpoints in brackets’ 利福平单药治疗金黄色葡萄球菌感染：关于不应用“括号内折点”的考量 Sara E Boyd and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3191–3193, REVIEWS（综述） 2 The Achilles’ heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing 特洛伊木马的致命弱点？头孢地尔药敏试验的系统评价 Deny Tsakri and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3194–3207, 3 Antifungal treatment strategies and their impact on resistance development in clinical settings 抗真菌治疗策略及其对临床环境中耐药性发展的影响 Norman Van Rhijn and P Lewis White Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3208–3226, ORIGINAL RESEARCH（论著） 4 Decrease in colistin resistance among young bovine and pig productions in France: relationship with colistin usage and stewardship measures 法国年轻牛和猪生产中多粘菌素耐药性的下降：与多粘菌素使用及管理措施的关系 Claire Chauvin and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3227–3235, 5 Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments 接受联合抗病毒治疗的活动性血液系统疾病患者感染SARS-CoV-2后恢复抗癌治疗的时间 E Matteini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3236–3241, 6 From TRIO to one: simplification to bictegravir/emtricitabine/tenofovir alafenamide in highly treatment-experienced people living with MDR HIV 从三联疗法到单一疗法：在多重耐药HIV感染且治疗经验丰富的人群中简化使用比克替拉韦/恩曲他滨/丙酚替诺福韦 José L Casado and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3242–3247, 7 Effects of commonly used antibiotics on children’s developing gut microbiomes and resistomes in peri-urban Lima, Peru 秘鲁利马市郊常用抗生素对儿童发育中的肠道微生物组和耐药组的影响 Neha Sehgal and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3248–3256, 8 Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study 衰弱指数实验室（FI-Lab）作为预测院内多重耐药肺炎克雷伯菌血流感染不良预后的指标：一项单中心回顾性队列研究 Carmen Pellegrino and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3257–3264, 9 Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes 体外衍生的产OXA-48样酶肺炎克雷伯菌突变体对头孢他啶/阿维巴坦的耐药机制 T Blanco-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3265–3272, 10 Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales 肠杆菌目中氨曲南/阿维巴坦药敏试验的纸片扩散法和肉汤微量稀释法的比较评价 Ioannis Baltas and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3273–3277, 11 Efficacy of topical hydrophilic gel of paromomycin combined with systemic or locally administered leishmanicidal drugs for treatment of experimental leishmaniasis caused by Leishmania (Viannia) braziliensis 硫酸巴龙霉素亲水性凝胶局部用药联合全身或局部使用杀利什曼原虫药物治疗巴西利什曼原虫（Viannia亚属）引起的实验性利什曼病的疗效 Líndicy Leidicy Alves and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3278–3287, 12 Population pharmacokinetics and dosing optimization of cefoselis in paediatric patients with haematological malignancies 血液系统恶性肿瘤患儿中头孢噻利的群体药代动力学及剂量优化 Jing-Rui Liu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3288–3296, 13 Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol 治疗产超广谱β-内酰胺酶（ESBL）和/或AmpC酶且不产碳青霉烯酶的肠杆菌目细菌的挑战：新型β-内酰胺/β-内酰胺酶抑制剂组合和头孢地尔的体外评价 Inès Rezzoug and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3297–3305, 14 Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study 使用多西环素进行暴露后预防（DoxyPEP）以在现实环境中预防性传播感染：PRIDOX研究 R Palacios and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3306–3310, 15 Risk–benefit balance of blood cultures among patients with stage IV cancer in unplanned admission: a nationwide propensity score–weighted study in Japan 日本全国范围内倾向评分加权研究：IV期癌症患者非计划入院时血培养的风险-获益平衡 Yuki Hashimoto and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3311–3319, 16 A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-κB inhibitors active against eumycetoma 对美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准的药物进行药物再利用筛选，发现两种对真性着色真菌病有活性的NF-κB抑制剂 Jingyi Ma and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3320–3328, 17 Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study 替莫西林与其他静脉注射β-内酰胺类药物治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究 Jeanne Iachkine and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3329–3334, 18 Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections 感染科医生对碳青霉烯耐药肠杆菌目感染的治疗偏好 Samuel E Cincotta and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3335–3339, 19 The aphA1 kanamycin and neomycin resistance gene originated in Klebsiella michiganensis aphA1卡那霉素和新霉素耐药基因起源于密歇根克雷伯菌 Robert A Moran and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3340–3344, 20 Global susceptibility profiles and potential resistance mechanisms of ceftazidime–avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020–23 data from the Antimicrobial Testing Leadership and Surveillance 头孢他啶-阿维巴坦耐药且不产碳青霉烯酶的碳青霉烯耐药肠杆菌目的全球易感性特征和潜在耐药机制：2020-2023年来自抗菌药物测试领导与监测的数据 Chih-Cheng Lai and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3345–3351, 21 Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa 头孢他啶-阿维巴坦联合氨曲南与固定组合氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较 Sophie E Müller and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3352–3356, 22 Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes 粪肠球菌中双重β-内酰胺协同作用及其与青霉素-头孢曲松感染性心内膜炎治疗结果的关系 April Gregson and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3357–3366, 23 The long walk to a short half-life: the discovery of augmented renal clearance and its impact on antibiotic dosing 走向短半衰期的漫长之路：发现肾增强清除及其对抗菌药物剂量调整的影响 Jeffrey Lipman and Russell E Lewis Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3367–3374, 24 Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections 氨曲南-阿莫西林/克拉维酸联合治疗产blaNDM肠杆菌目感染 Efrat Orenbuch-Harroch and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3375–3380, 25 Evaluation of sodium zirconium cyclosilicate usage for hyperkalaemia secondary to sulfamethoxazole/trimethoprim therapy 评估锆酸钠环硅酸盐用于磺胺甲恶唑/甲氧苄啶治疗继发的高钾血症 Dixie Pyles and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3381–3385, 26 Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis 每周三次血液透析后使用头孢他啶可在类鼻疽患者中达到足够的透析前浓度并实现临床治愈 Simon Smith and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3386–3390, 27 In vitro and clinical data demonstrate negligible risk of drug–drug interactions with opelconazole, a novel inhaled antifungal agent 体外和临床数据表明，新型吸入抗真菌药物奥培康唑的药物-药物相互作用风险可忽略不计 Lindsey M R Cass and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3391–3400, 28 Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial 在ALLG AMLM16试验中，FLT3-ITD阳性急性髓系白血病患者在初始诱导和巩固治疗期间接受索拉非尼治疗时的抗真菌预防 Chin Fen Neoh and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3401–3406, 29 The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections 基于替加环素的联合用药对多重耐药鲍曼不动杆菌引起的血流感染的协同活性 Huan Zhang and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3407–3418, 30 Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage? 儿科患者中哌拉西林的剂量调整与肾增强清除：现行指南是否足以达到治疗浓度覆盖？ Anne Ravix and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3419–3430, 31 Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model 在中性粒细胞减少的小鼠大腿感染模型中评估人模拟氨曲南-阿维巴坦对嗜麦芽窄食单胞菌的疗效 Yakun Fu and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3431–3437, 32 A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study) 西班牙HIV感染者长期使用卡博特韦和利匹韦林的有效性和持久性的前瞻性评估（RELATIVITY研究） Luis Buzón-Martín and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3438–3451, 33 Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus 奥洛罗芬和伏立康唑对烟曲霉的体外拮抗作用 Illan Laloum and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3452–3461, RESEARCH LETTERS（研究快讯） 34 Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury 静脉注射万古霉素联用导致大剂量甲氨蝶呤清除延迟和急性肾损伤 Thao Dao and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3462–3464, 35 Overestimation of piperacillin/tazobactam resistance in Escherichia coli by disc diffusion and gradient strip methods 纸片扩散法和梯度条法高估大肠埃希菌对哌拉西林/他唑巴坦的耐药性 Stefano Mancini and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3464–3467, 36 Mind the gap: missed re-initiation and monitoring in statin–antimicrobial co-prescriptions 注意差距：他汀类药物与抗菌药物联合处方中的漏重新起始和监测 Melwin Kyle Solis and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3467–3468, 37 Pharmacokinetics of aztreonam/avibactam in a critically ill patient with a class B metallo-β-lactamase producing Enterobacteriaceae and receiving continuous renal replacement therapy 一名接受连续肾脏替代治疗且感染产B类金属β-内酰胺酶肠杆菌科细菌的重症患者中氨曲南/阿维巴坦的药代动力学 Daniel Fresán and others Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3469–3471, CORRECTION（更正） 38 Correction to: Systematic reviews and the Journal of Antimicrobial Chemotherapy; past, present and future. A systematic reappraisal 更正：系统评价与《抗菌药物化疗杂志》：过去、现在和未来。一项系统再评价 Journal of Antimicrobial Chemotherapy, Volume 80, Issue 12, December 2025, Pages 3472–3473,

100 项与环硅酸锆钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10727	环硅酸锆钠	V03AE10	DB14048

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高钾血症	欧盟	AstraZeneca AB	2018-03-22
高钾血症	冰岛	AstraZeneca AB	2018-03-22
高钾血症	列支敦士登	AstraZeneca AB	2018-03-22
高钾血症	挪威	AstraZeneca AB	2018-03-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床3期	美国	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	中国	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	日本	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	阿根廷	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	巴西	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	保加利亚	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	加拿大	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	印度	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	意大利	AstraZeneca PLC	2021-09-30
慢性肾病	临床3期	马来西亚	AstraZeneca PLC	2021-09-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04676646 (REALIZE-K, CTgov)	临床4期	射血分数降低的心力衰竭 \| 高钾血症	366	Placebo+Spironolactone+Sodium zirconium cyclosilicate	簾齋廠繭餘糧醖壓壓餘(築淵廠製觸繭製獵廠鏇) = 齋齋積襯觸觸艱糧鏇糧觸衊餘觸艱餘鹽積構襯 (夢鑰膚獵網憲齋構構艱, 膚獵艱憲蓋壓選淵觸範 ~ 鬱窪憲製艱構遞繭醖衊) 更多	-	2025-07-09
NCT04847232 (CTgov)	临床3期	心律失常 \| 高钾血症	2,690	SZC Placebo	鏇廠網膚蓋選製壓構遞 = 遞淵膚淵淵製糧廠製遞醖襯餘夢憲蓋網廠壓選 (獵鹹醖遞憲夢醖艱醖襯, 鹹衊蓋遞繭繭製糧淵遞 ~ 餘觸餘鹽製壓艱醖鑰壓) 更多	-	2025-06-18
NCT04983979 (ORTIZ, CTgov)	临床2期	2型糖尿病 \| 糖尿病肾病 \| 慢性肾病 ... 更多	18	Placebo	餘製獵繭構獵獵壓鏇觸(齋蓋顧夢構鹹觸顧窪膚) = 製鬱築顧網糧夢艱遞窪觸艱壓窪繭獵餘夢鹹糧 (築鹽醖餘觸顧壓齋範遞, 0.42) 更多	-	2025-06-08
NCT06029179 (Pubmed \| BMC Nephrol)	N/A	高钾血症	120	Sodium zirconium cyclosilicate (SZC)	餘憲鹹遞鹽願鑰蓋淵積(鹽艱廠鬱網鹹範膚鹽願) = 鏇糧鏇艱蓋構淵遞鬱製壓積積窪艱鹹觸襯餘構 (糧襯齋簾選襯鑰網鹹鹽 )	积极	2025-05-06
				Sodium polystyrene sulfonate (SPS)	餘憲鹹遞鹽願鑰蓋淵積(鹽艱廠鬱網鹹範膚鹽願) = 艱鑰顧築鹹鏇鏇選獵齋壓積積窪艱鹹觸襯餘構 (糧襯齋簾選襯鑰網鹹鹽 )
NCT04676646 (REALIZE-K, Literature) 人工标引	临床4期	心脏衰竭 \| 高钾血症	203	Sodium Zirconium Cyclosilicate (SZC)	築簾夢蓋顧簾窪夢膚選(鹽遞積壓鏇壓顧艱鹽遞) = 糧壓憲製膚鑰遞觸選築憲鏇窪獵蓋繭鏇構簾醖 (糧糧餘鹽範構顧齋範範 ) 更多	积极	2024-11-18
				Placebo	築簾夢蓋顧簾窪夢膚選(鹽遞積壓鏇壓顧艱鹽遞) = 襯鑰齋鹽獵積壓蓋蓋齋憲鏇窪獵蓋繭鏇構簾醖 (糧糧餘鹽範構顧齋範範 ) 更多
GALVANIZE (AHA2024) 人工标引	N/A	高钾血症	-	Sodium zirconium cyclosilicate (long-term)	鬱齋廠網蓋衊繭窪簾憲(窪鹹淵觸壓窪憲膚憲網) = 網鑰鏇構積鏇積壓遞醖遞壓衊觸繭鹹壓網範艱 (繭簾憲餘夢築鬱廠艱範 ) 更多	积极	2024-11-11
				Sodium zirconium cyclosilicate (short-term)	鬱齋廠網蓋衊繭窪簾憲(窪鹹淵觸壓窪憲膚憲網) = 遞衊網顧廠廠醖範網鑰遞壓衊觸繭鹹壓網範艱 (繭簾憲餘夢築鬱廠艱範 ) 更多
NCT04676646 (REALIZE-K, Pubmed \| J Am Coll Cardiol)	临床4期	高钾血症	203	Sodium Zirconium Cyclosilicate (SZC)	鹹蓋壓襯觸淵淵齋壓獵(鑰鹽淵簾網獵築廠襯廠) = 獵願糧蓋衊夢憲顧願醖積糧襯觸繭夢獵簾網鏇 (餘築簾遞糧窪廠夢襯醖 )	积极	2024-11-01
				Placebo	鹹蓋壓襯觸淵淵齋壓獵(鑰鹽淵簾網獵築廠襯廠) = 網餘廠簾願窪窪鏇糧窪積糧襯觸繭夢獵簾網鏇 (餘築簾遞糧窪廠夢襯醖 )
Actualize (ASN2024)	N/A	高钾血症	1,320	Sodium Zirconium Cyclosilicate (SZC) (correction phase)	鹽鏇窪膚築醖製積艱構(獵膚齋選蓋範襯廠鹹鑰) = 積願憲憲積淵繭餘衊餘廠餘餘窪鏇網簾鏇遞積 (築窪窪鬱艱鏇顧遞鹽鹽 ) 更多	积极	2024-10-24
				Sodium Zirconium Cyclosilicate (SZC) (maintenance phase)	鹽鏇窪膚築醖製積艱構(衊餘廠襯醖鏇觸鹽繭積) = 積醖憲餘膚夢鑰鹽鹹蓋積糧窪廠築淵範鑰觸齋 (壓襯壓夢製網憲艱鏇顧 ) 更多
GALVANIZE Outcome (ASN2024)	N/A	终末期肾脏病	1,010	Long-term SZC use	範簾築簾鏇鏇顧繭範醖(艱膚鏇鏇窪壓窪鏇襯壓): P-Value = <0.05 更多	积极	2024-10-24
				Short-term SZC use
NCT03528681 (HARMONIZE Asia, Pubmed \| Clin Ther)	临床3期	高钾血症	270	Sodium Zirconium Cyclosilicate 5g	壓憲衊鬱衊鬱範構積簾(鏇範窪衊選積顧觸淵選) = driven primarily by peripheral edema and constipation 簾獵製廠鹽鹹淵襯襯艱 (製衊艱網壓繭構繭膚範 )	积极	2024-08-06
				Sodium Zirconium Cyclosilicate 10g